indazoles has been researched along with piperidines in 247 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (1.21) | 18.7374 |
| 1990's | 9 (3.64) | 18.2507 |
| 2000's | 20 (8.10) | 29.6817 |
| 2010's | 116 (46.96) | 24.3611 |
| 2020's | 99 (40.08) | 2.80 |
| Authors | Studies |
|---|---|
| Niewegòwska, W; Wrzeciono, U | 1 |
| Felińska, W; Linkowska, E; Wrzeciono, U | 1 |
| Bernardi, M; Di Sarra, B; Montecchiani, G; Re, L; Rossini, L; Tonnini, C | 1 |
| Angel, I; Garreau, M; Langer, SZ; Prouteau, M; Schoemaker, H | 1 |
| Bloomquist, W; Calligaro, DA; Cohen, I; Cohen, ML; Schaus, JM; Susemichel, AD; Thompson, DC | 1 |
| Hicks, C; O'Neill, MJ; Ward, M | 1 |
| Labeaga, L; Mosquera, R; Orjales, A; Rodes, R | 1 |
| Wiley, JL | 1 |
| Foxx-Orenstein, AE; Grider, JR; Jin, JG | 1 |
| Furukawa, T; Katsuragi, T; Kushiku, K; Noguchi, H; Ono, N; Yamada, H; Yamada, K | 1 |
| Hisa, H; Hosokawa, A; Kimura, T; Masada, K; Nagayama, T; Satoh, S; Suzuki-Kusaba, M; Yoshida, M | 1 |
| Morales, M; Oz, M; Zhang, L | 1 |
| Fang, M; Fisher, LL; Kovács, KJ; Larson, AA | 1 |
| Ogonowski, AA; Smith, JB | 1 |
| COHEN, MP; SHAVEL, J; VONSTRANDTMANN, M | 1 |
| Carai, MA; Grella, GE; Lazzari, P; Loriga, G; Murineddu, G; Mussinu, JM; Pani, L; Pinna, GA; Ruiu, S | 1 |
| Bianciotti, LG; di Nunzio, A; Hope, SI; Legaz, G; Morgazo, C; Perfume, G; Vatta, MS | 1 |
| Engel, DC; Maas, AI; Slemmer, JE; Vlug, AS; Weber, JT | 1 |
| Brodjian, S; Brune, M; Bush, E; Collins, CA; Dayton, B; Engstrom, KM; Falls, DH; Freeman, JC; Gao, J; Hernandez, LE; Kym, PR; Lynch, JK; Marsh, KC; Mulhern, MM; Shapiro, RD; Souers, AJ; Vasudevan, A; Verzal, MK; Wagaw, SH; Wodka, D | 1 |
| Brodjian, S; Campbell, TJ; Collins, CA; Dayton, BD; Freeman, JC; Fryer, RM; Gao, J; Hernandez, L; Iyengar, R; Judd, AS; Kym, PR; Lynch, JK; Marsh, KC; Mulhern, M; Napier, JJ; Polakowski, JS; Preusser, LC; Reilly, RM; Reinhart, GA; Segreti, JA; Sham, HL; Souers, AJ; Vasudevan, A; Wagaw, SH; Wodka, D; Zhao, G | 1 |
| Basso, AM; Bratcher, NA; Brune, ME; Collins, CA; Cowart, MD; Esbenshade, TA; Fox, GB; Gallagher, KB; Hancock, AA; Iyengar, R; Kym, PR; Rueter, LE; Schmidt, M; Souers, AJ; Sun, M; Vasudevan, A; Zhao, C | 1 |
| Cameron, MD; Feng, Y; Frackowiak, B; Griffin, E; Lin, L; LoGrasso, P; Ruiz, C; Schröter, T | 1 |
| Kibble, A | 1 |
| Armand, JP; Mir, O; Ropert, S | 1 |
| Sherman, SI | 2 |
| Izumi, N; Kagokawa, H; Kawahara, A; Nagaoka, T; Sato, E; Sogawa, K; Takahashi, A; Yoshida, A | 1 |
| Chen, HH; France, CP; Glennon, RA; Kelly, CR; Li, JX; Liao, JC; May, JA; Rice, KC; Sharif, NA; Young, R | 1 |
| Döme, B; Magyar, M | 1 |
| Comery, TA; Di, L; Kerns, EH; Kowal, DM; Liu, KG; Lo, JR; Robichaud, AJ; Schechter, LE; Smith, DL; Zhang, GM; Zhang, JY | 1 |
| Altamura, S; Boueres, J; Ferrigno, F; Fonsi, M; Giomini, C; Jones, P; Lamartina, S; Monteagudo, E; Ontoria, JM; Orsale, MV; Palumbi, MC; Pesci, S; Roscilli, G; Rowley, M; Scarpelli, R; Schultz-Fademrecht, C; Toniatti, C | 1 |
| Moretti, S; Puxeddu, E; Romagnoli, S; Voce, P | 1 |
| Abad, MC; Gibbs, AC; Kuo, LC; Lewandowski, FA; Struble, GT; Sui, Z; Sun, W; Tounge, BA; Zhang, X | 1 |
| Egashira, N; Ikesue, H; Kawashiri, T; Mihara, Y; Oishi, R; Sada, H; Ushio, S; Yano, T | 1 |
| Cheng, CY; Lie, PP; Lui, WY; Mok, KW; Mruk, DD | 1 |
| Axten, JM; Becker, CJ; Blackledge, CW; Bobko, MA; Brady, PG; Campobasso, N; Chadderton, AR; Dumble, M; Duquenne, C; Feng, Y; Gardiner, CM; Gilbert, S; Grant, SW; Heerding, D; Li, WH; Liu, Q; Medina, JR; Miller, WH; Rabindran, SK; Romeril, SP; Scherzer, D; Shu, A; Sudakin, V; Ward, P; Xiang, H | 1 |
| Alves, MM; de Groot, JW; Hofstra, RM; Links, TP; Osinga, J; Plukker, JT; Verbeek, HH | 1 |
| Li, YQ; Mei, XP; Wang, W; Wei, YY; Wu, SX; Xu, LX; Zhang, MM; Zhang, T | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Chevreau, C; Cottura, E; Garrido-Stowhas, I; Sibaud, V | 1 |
| Ang, KK; Buchholz, T; Buser-Doepner, C; Mason, KA; Mathur, A; Milas, L; Toniatti, C; Valdecanas, D; Wang, L | 1 |
| Goozner, M | 1 |
| Bader, SJ; Bagley, SW; Bernhardson, DJ; Cabral, S; Edmonds, DJ; Griffith, DA; Kung, DW; Polivkova, J; Rose, CR; Southers, JA; Yang, X | 1 |
| Knochel, P; Unsinn, A | 1 |
| Döme, B; Török, S | 1 |
| Lazzari, P; Mastinu, A; Pani, L; Pinna, GA; Pira, M | 1 |
| Cserepes T, M; Döme, B; Rényi-Vámos, F; Török, S | 1 |
| Belvin, M; Berry, L; Choo, EF; Lewin-Koh, N; Merchant, M; Ng, CM; Salphati, L | 1 |
| Benakanakere, I; Besch-Williford, C; Carroll, CE; Hyder, SM; Liang, Y | 1 |
| Bhargava, S; Chen, J; Haas-Kogan, DA; Kolkowitz, I; Matthay, KK; Molinaro, AM; Mueller, S; Olow, A; Orbach, S; Wehmeijer, N; Yang, X | 1 |
| Robert, C; Sibaud, V | 1 |
| Baird, RD; Carpenter, CL; Chatterjee, M; de Bono, JS; Forster, M; Gevensleben, H; Hylands, L; Iannone, R; Kaye, SB; Kreischer, N; Loughney, J; Miranda, S; Moreno, V; Omlin, A; Riisnaes, R; Sandhu, SK; Schelman, WR; Sun, L; Thway, K; Toniatti, C; Wenham, RM; Wilding, G | 1 |
| Burris, HA; Infante, JR | 1 |
| André, F; Ashworth, A; Bajrami, I; Dorvault, N; Elliott, R; Fontebasso, Y; Friboulet, L; Lord, CJ; Olaussen, KA; Postel-Vinay, S; Soria, JC | 1 |
| Bakalarski, CE; Belvin, M; Bustos, DJ; Chan, J; Dogan, T; Friedman, LS; Hoeflich, KP; Kirkpatrick, DS; Phu, L; Song, Q; Young, A | 1 |
| Konstantinopoulos, PA; Liu, JF; Matulonis, UA | 1 |
| Bridges, KA; Buchholz, TA; Buser, CA; Liu, H; Meyn, RE; Toniatti, C | 1 |
| Bridges, TM; Chase, P; Cho, HP; Conn, PJ; Daniels, JS; Gentry, PR; Hodder, PS; Kokubo, M; Lamsal, A; Lindsley, CW; Niswender, CM; Noetzel, MJ; Smith, E; Wood, MR | 1 |
| Dhingra, D; Gilhotra, N | 1 |
| Chen, Y; Hong, S; Luo, S; Tan, M; Wang, S; Zhang, L | 1 |
| Bou-Reslan, H; Cao, T; Carano, R; Castillo, J; Chan, E; Cheng, JH; Clermont, AC; Devasthali, V; Forrest, W; French, D; Hoeflich, KP; Junttila, MR; Merchant, M; Metcalfe, C; Nannini, MA; Otter, DD; Singh, M | 1 |
| Jones, P; Rowley, M; Toniatti, C; Wilcoxen, K | 1 |
| Bustos, D; Kirkpatrick, DS; Phu, L; Varfolomeev, E; Vucic, D; Yu, K | 1 |
| Carletti, F; Ferraro, G; Gambino, G; Rizzo, V; Sardo, P | 1 |
| DiGiammarino, EL; Donawho, CK; Gao, W; Hopkins, TA; Johnson, EF; Maag, D; Olson, AM; Osterling, DJ; Panchal, SC; Rodriguez, LE; Shi, Y; Solomon, LR; Stolarik, DF; Wilsbacher, JL | 1 |
| Seimiya, H | 1 |
| Covell, LL; Ganti, AK | 1 |
| Agnihotri, S; Buczkowicz, P; Chornenkyy, Y; Dirks, PB; Garzia, L; Golbourn, B; Hawkins, C; Leung, S; Rakopoulos, P; Rutka, JT; Siddaway, R; Taylor, MD; Yu, M | 1 |
| Castelli, MP; Davidson, C; De Luca, MA; Di Chiara, G; Kellett, K; Loi, B; Martorelli, M; Miliano, C; Porcu, A; Schifano, F; Stair, JL | 1 |
| Beno, BR; Chaturvedula, PV; Civiello, RL; Conway, CM; Dubowchik, GM; Han, X; Herbst, JJ; Macor, JE; Xu, C | 1 |
| Alexandre, J; Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Bretagne, M; Cabanes, L; Cessot, A; Chahwakilian, A; Coriat, R; Goldwasser, F; Huillard, O; Orvoen, G; Thomas-Schoemann, A; Tlemsani, C | 1 |
| Allegra, M; Bozzi, Y; Caleo, M; Cerri, C; Genovesi, S; Guglielmotti, A; Perry, VH; Pistillo, F; Püntener, U | 1 |
| Mullard, A | 1 |
| Borea, PA; Canazza, I; De Luca, MA; Di Rosa, F; Fantinati, A; Gregori, A; Margiani, G; Marti, M; Ossato, A; Rimondo, C; Serpelloni, G; Trapella, C; Varani, K; Vincenzi, F | 1 |
| AlHilli, MM; Becker, MA; Flatten, KS; Haluska, P; Harrell, MI; Harrington, SC; Hawthorne, KM; Hou, X; Hurley, RM; Kalli, KR; Kaufmann, SH; Maurer, MJ; McKinstry, S; Meng, XW; Oberg, AL; Swisher, EM; Weroha, SJ; Wilcoxen, KM | 1 |
| Agarwal, S; Balser, JP; Ben-Baruch, NE; Benigno, B; Berek, JS; Buscema, J; Christensen, RD; du Bois, A; Dørum, A; Fabbro, M; Follana, P; Gilbert, L; González-Martín, A; Herrstedt, J; Ledermann, JA; Lorusso, D; Mądry, R; Mahner, S; Marth, C; Matulonis, UA; Mirza, MR; Monk, BJ; Oza, AM; Redondo, A; Rimel, BJ; Rosenberg, P; Tinker, AV; Vergote, I | 1 |
| Barr, M; Cuffe, S; Finn, S; Gately, K; Heavey, S; Leonard, N; McVeigh, N; Nicholson, S; O'Byrne, K; Ryan, R; Young, V | 1 |
| Agarwal, S; Beijnen, JH; Gebretensae, A; Hughes, L; Kansra, V; Lu, S; Rosing, H; Schellens, JHM; Tibben, MM; van Andel, L; Zhang, Z | 1 |
| Li, J | 1 |
| Carter, JJ; Fretwell, LV; Woolard, J | 1 |
| Cohen, MS; Ekblad, T; Karlberg, T; Löw, M; Moche, M; Pinto, AF; Schüler, H; Thorsell, AG; Trésaugues, L | 1 |
| Craveiro, RB; Dilloo, D; Ehrhardt, M; Goetz, B; Olschewski, M; Pietsch, T; Velz, J | 1 |
| Scott, LJ | 1 |
| Asano, T; Hayashi, Y; Hisatsune, K; Ishii, A; Kusano, M; Moriyasu, T; Nakajima, J; Taki, K; Tsuchihashi, H; Zaitsu, K | 1 |
| Lorusso, D; Sabatucci, I | 1 |
| George, TJ; Hromas, R; Jaiswal, AS; Jones, D; Najmunnisa, N; Sidhu, GS; Srinivasan, G; Wilcoxen, K; Williamson, EA | 1 |
| Beijnen, JH; Gebretensae, A; Hughes, L; Kansra, V; Rosing, H; Sanghvi, M; Schellens, JHM; Tibben, MM; van Andel, L; Zhang, Z | 1 |
| Bhutkar, A; Chen, PY; Chung, KM; Dorans, KJ; Hong, E; Jacks, T; Muzumdar, MD; Noll, EM; Sprick, MR; Trumpp, A | 1 |
| Agarwal, S; Burris, H; Kansra, V; Moore, K; Patel, MR; Zhang, ZY | 1 |
| Matulonis, UA; Mirza, MR; Moore, KN | 1 |
| Avogadri-Connors, F; Booth, L; Cutler, RE; Dent, P; Lalani, AS; Poklepovic, A; Roberts, JL; Samuel, P | 1 |
| Buclin, T; Cagnon, L; Cardoso, E; Csajka, C; Decosterd, L; Diezi, M; Ellefsen-Lavoie, K; Homicsko, K; Mercier, T; Michielin, O; Wagner, AD; Widmer, N | 1 |
| Longoria, TC; Tewari, KS | 1 |
| Gillard, M; Lee, JM; Lipkowitz, S; Zimmer, AS | 1 |
| Amiri-Kordestani, L; Banerjee, A; Beaver, JA; Blumenthal, GM; Charlab, R; Chen, XH; Dave, K; Dinin, J; Eradiri, O; Ghosh, S; Goldberg, KB; Horne, HN; Howie, LJ; Ibrahim, A; Ison, G; Janoria, KG; Kelly, SL; Kluetz, PG; Lee, EY; Li, F; Manheng, W; Palmby, TR; Pazdur, R; Philip, R; Pierce, WF; Pierre, V; Ramamoorthy, A; Song, P; Sridhara, R; Tang, S; Yu, J; Zhang, L | 1 |
| Mountzios, G; Papadimitriou, CA; Papadimitriou, M | 1 |
| Berek, JS; Berton-Rigaud, D; Colombo, N; Ellard, S; Ghatage, P; Gonzalez-Martin, A; Guo, W; Hazard, S; Ledermann, J; Lesoin, A; Madry, R; Mahner, S; Matulonis, UA; Mirza, MR; Peen, U; Pineda, M; Redondo, A; Reinthaller, A; Rosengarten, O; Sehouli, J; Vergote, I | 1 |
| Lorusso, D; Pignata, S | 1 |
| Domchek, SM | 1 |
| Ethier, JL; Lheureux, S; Oza, AM | 1 |
| Konstantinopoulos, PA; Matulonis, UA | 1 |
| Essel, KG; Moore, KN | 1 |
| Booth, L; Dent, P; Poklepovic, A; Rais, R; Roberts, JL | 1 |
| Bourn, J; Cekanova, M | 1 |
| Agarwal, S; Banerjee, S; Benigno, B; Berek, JS; Berton-Rigaud, D; Buscema, J; D'Hondt, V; Del Campo, JM; Hilpert, F; Hudgens, S; Lund, B; Malander, S; Matulonis, UA; Mirza, MR; Oza, AM; Provencher, D; Scambia, G; Sehouli, J; Tinker, AV; Vázquez, IP | 1 |
| Aoki, D; Chiyoda, T | 1 |
| Duggan, ST; Heo, YA | 1 |
| O'Cearbhaill, RE | 1 |
| Gan, N; Li, H; Sun, Q; Tang, P; Wu, D; Xie, T; Zhang, Y | 1 |
| Monga, DK; Patibandla, NS | 1 |
| Al-Kawaz, A; Ali, R; Band, V; Green, AR; Madhusudan, S; Mesquita, KA; Miligy, IM; Mirza, S; Rakha, EA; Seedhouse, C; Toss, MS | 1 |
| Baldini, C; Banerjee, S; Battisti, NML; Dumas, L; Kadambi, S; Lichtman, SM; Liposits, G; Loh, KP; Soto-Perez-de-Celis, E | 1 |
| Bauer, J; Grimm, D; Grosse, J; Infanger, M; Kopp, S; Krüger, M; Milling, RV; Wehland, M | 1 |
| Berta, K; Csabai, I; Klus, GT; Mikule, K; Pipek, O; Póti, Á; Ried, T; Szallasi, Z; Szüts, D; Wilcoxen, K; Xiao, Y | 1 |
| Fisher, M; Guy, H; Walder, L | 2 |
| Nugent, E; Smith, JA; Tomasino, T; Tran, AT; Zhong, L | 1 |
| Wu, L; Zhong, L | 1 |
| Coleman, RL; Kurnit, KC; Westin, SN | 1 |
| Banerjee, S; Bover, I; Dørum, A; Fabbro, M; Follana, P; Goffin, F; Harter, P; Hazard, SJ; Hellman, K; Mahner, S; Matulonis, UA; Mirza, MR; Moore, KN; Pineda, MJ; Provencher, D; Shapira-Frommer, R; Tinker, AV; Tognon, G; Vázquez, IP; Wenham, RM | 1 |
| Bai, H; Jiang, X; Li, W; Li, X; Zhang, Z | 1 |
| Callahan, T; Chan, JK; Guo, W; Moore, K; Patel, MR; Secord, AA; Zhang, ZY | 1 |
| Federico, L; Feng, B; Feng, N; Hanke, J; Ma, X; Marszalek, JR; Mikule, K; Mills, GB; Ramaswamy, S; Sun, K; Vellano, CP; Wang, J; Wang, Z; Xiao, Y | 1 |
| Cohn, DE; Ehrisman, JA; Foote, JR; Havrilesky, LJ; Jewell, E; Liang, MI; Secord, AA | 1 |
| Azodi, M; Berek, JS; Chan, JK; Cloven, N; Cristea, M; DiSilvestro, P; Fleming, GF; Geller, MA; Li, Y; Luptakova, K; Matei, DE; Matulonis, UA; Miller, DS; Monk, BJ; Moore, KN; Oza, AM; Rimel, BJ; Secord, AA; Sun, K; Wahner Hendrickson, AE | 1 |
| Fagotti, A; Marchetti, C; Scambia, G | 1 |
| Bendell, J; Chan, IT; Cleary, JM; de Crespigny, A; Fredrickson, J; Gates, MR; Hsieh, HJ; Jones, S; Kurkjian, C; Kwak, E; LoRusso, P; Musib, L; Pandya, S; Pilat, MJ; Rudin, CM; Shapiro, GI; Wongchenko, M; Yan, Y | 1 |
| Campbell, JD; Chapman, RH; Kumar, VM; McQueen, RB; Whittington, MD | 1 |
| Carter, JJ; Cooper, SL; March, J; Woolard, J | 1 |
| Bedel, J; Cameron, T; Goble, S; Isaacson, J; Maloney, L; Wallace, K | 1 |
| Arora, S; Benigno, B; Berek, JS; Canzler, U; Del Campo, JM; Follana, P; Gil-Martin, M; Gilbert, L; Hazard, SJ; Lesoin, A; Lund, B; Mahner, S; Malander, S; Matulonis, UA; Mirza, MR; Monk, BJ; Oza, AM; Provencher, D; Waters, J; Wenham, RM; Woie, K | 1 |
| Chen, W; Fan, J; Fu, X; Gao, H; Han, Y; Jin, X; Ju, D; Liu, H; Luan, J; Tang, S; Wu, Z; Zai, W; Zhang, X | 1 |
| Balmaña, J; Castroviejo-Bermejo, M; Cruz, C; de Bono, JS; Kaye, SB; Lord, CJ; Mateo, J; Oaknin, A; Serra, V; Tutt, A | 1 |
| Aguilera, J; Behbakht, K; Bitler, BG; Brennecke, EP; Cittelly, DM; Ferguson, R; Joglar, AM; Kim, H; McMellen, A; Moldovan, GL; Nurmemmedov, E; Sikora, MJ; Thakar, T; Watson, ZL; Wilson, H; Yamamoto, TM | 1 |
| Akritidou, MA; Anagnostopoulos, A; Belloni, D; Chartomatsidou, E; Ferrero, E; Ghia, P; Kotta, K; Ntoufa, S; Papakonstantinou, N; Rosenquist, R; Rovida, A; Stamatopoulos, K; Stavroyianni, N; Trangas, T | 1 |
| Åvall-Lundqvist, E; Bergmann, TK; Birrer, MJ; Bjørge, L; Brøsen, K; Christensen, RD; Jørgensen, M; Lassen, U; Mäenpää, J; Malander, S; Mau-Sørensen, M; Mirza, MR; Nielsen, F; Roed, H | 1 |
| Gao, Y; Hei, Y; Hou, J; Ji, D; Li, W; Lou, G; Milton, A; Wang, D; Wang, W; Wu, X; Xia, B; Yan, J; Yin, R; Zhang, J; Zhang, ZY; Zheng, H | 1 |
| Gray, S; Khor, XY; Yiannakis, D | 1 |
| Schorge, JO | 1 |
| Anttila, M; Åvall Lundqvist, E; Birrer, MJ; Bjørge, L; dePont Christensen, R; Dimoula, M; Hietanen, S; Krog Vistisen, A; Lindahl, G; Lund, B; Mäenpää, JU; Malander, S; Mirza, MR; Nyvang, GB; Peen, U; Roed, H; Staff, S; Werner, TL; Ør Knudsen, A | 1 |
| Banerjee, S; Benigno, B; Bessette, P; Buscema, J; Casado Herraez, A; Gil-Martin, M; Guy, H; Hardy-Bessard, AC; Kalbacher, E; Lau, S; Ledermann, JA; Lindahl, G; Mahner, S; Marmé, F; Matulonis, UA; Mirza, MR; Nøttrup, TJ; Travers, K; Walder, L; Wenham, RM; Woie, K | 1 |
| Fletcher, SP; Goetzke, FW; González, J; van Dijk, L | 1 |
| Cui, M; Han, L; Wang, L; Wang, Q; Xu, Y | 1 |
| Backes, F; Barretina-Ginesta, P; Baumann, K; Bradley, WH; Bruchim, I; DePont Christensen, R; Freyer, G; González-Martín, A; Graybill, W; Gupta, D; Haggerty, AF; Hoskins, P; Jardon, K; Li, Y; Lorusso, D; Lund, B; Malinowska, IA; Mangili, G; McCormick, C; Mirza, MR; Monk, BJ; Moore, RG; O'Cearbhaill, RE; Pothuri, B; Redondo, A; Rubio-Pérez, MJ; Shahin, MS; Sun, K; Vergote, I; Vulsteke, C | 1 |
| Dianin, V; Fillo, S; Lista, F; Mattarei, A; Megighian, A; Montecucco, C; Negro, S; Pirazzini, M; Rigoni, M; Tombesi, G; Valentini, A; Zanetti, G; Zugno, A | 1 |
| Gourd, E | 1 |
| Ji, Y; Li, L; Sun, G; Wang, Q; Ye, L; Zhao, Q; Zhao, S | 1 |
| Amaravadi, RK; Bast, RC; Becker, SE; Heinzen, EP; Hou, X; Llombart-Cussac, A; Lu, Z; Matias-Guiu, X; Maurer, MJ; Oberg, AL; Pang, L; Poveda, A; Rask, P; Romero, I; Rubio, MJ; Santacana, M; Santiago-O'Farrill, JM; Weroha, SJ | 1 |
| Fillo, S; Lista, F; Mattarei, A; Megighian, A; Montecucco, C; Negro, S; Pirazzini, M; Rigoni, M; Zanetti, G | 1 |
| Chen, FE; Gu, SX; Liu, GY; Meng, G; Pannecouque, C; Tang, JF; Wu, FS; Xiao, T; Xu, ZQ; Zhu, YY | 1 |
| Long, X; Zhou, Q; Zou, D | 1 |
| Walsh, CS | 1 |
| Longo, DL | 1 |
| Konstantinopoulos, PA; Vinayak, S | 1 |
| Lin, J; Yang, X; Zhao, H | 1 |
| Rodrigues, M | 1 |
| Al-Lazikani, B; Ameratunga, M; Antolin, AA; Banerji, U; Clarke, PA; Workman, P | 1 |
| Bridges, KA; Clump, DA; Faust, AZ; Ferris, RL; Frederick, MJ; Heffernan, TP; Mason, KA; Meyn, RE; Molkentine, DP; Molkentine, JM; Myers, JN; Pickering, CR; Sheth, A; Skinner, HD; Xie, T; Yang, L | 1 |
| Capriati, V; Cardoso, SM; Chaves, S; Costa, M; Gwizdala, K; Josselin, R; Pereira-Santos, AR; Piemontese, L; Resta, S; Rinaldo, F; Santos, MA | 1 |
| Bhatti, A; Horton, ER; Kerliu, L; Myruski, S; Pervanas, HC; Petrosius, P; Soni, P | 1 |
| Bai, J; Kristeleit, R; Monk, BJ; Moore, KN; Tewari, KS; Wolford, JE | 1 |
| Casado, J; Chen, YA; Chowdhury, D; D'Andrea, AD; Dezube, BJ; Färkkilä, A; Garcia, E; Graham, JR; Gulhan, DC; Hautaniemi, S; Jacobson, CA; Kochupurakkal, B; Konstantinopoulos, PA; Lako, A; Maliga, Z; Matulonis, UA; Munster, P; Nguyen, H; Park, PJ; Rodig, S; Santagata, S; Schapiro, D; Shapiro, GI; Sorger, PK; Swisher, EM; Yapp, C; Zhou, Y | 1 |
| da Costa, A | 1 |
| Carter, Z; Jewett, BE; Ligon, LA; Miller, MN; Mohammad, I; Ordway, GA | 1 |
| Ai, Z; Bao, W; Chen, X; Feng, Y; Gao, W; Huang, H; Jia, H; Jiang, R; Jiang, W; Li, J; Li, Y; Liu, J; Luan, Y; Shi, T; Teng, Y; Wang, X; Wu, S; Yin, S; Yu, A; Zang, R; Zhang, J; Zhang, P; Zhang, W; Zhang, Y; Zhu, J; Zhu, T; Zhu, Y | 1 |
| Cao, J; Chen, M; Frank, SJ; Jiang, B; Li, Y; Lin, E; Myers, JN; Sahoo, N; Wang, L; Wang, X; Wang, Z; Zhang, R; Zhang, X; Zhu, XR | 1 |
| Dang, TT; Morales, JC | 1 |
| Ayari, H; Boissier, E; Cohen, R; Combe, P; Courbebaisse, M; Crespel, C; Delanoy, N; Karras, A; Lazareth, H; Mercadier-Riaz, E; Pallet, N; Thervet, E | 1 |
| Barrington, DA; Cohn, DE; Senter, L; Smith, HJ; Straughn, JM; Tubbs, C | 1 |
| Distel, LV; Fietkau, R; Hecht, M; Heinzerling, L; Jost, T; Knippertz, I; Weigert, V | 1 |
| Chase, DM; Eakin, CM; Ewongwo, A; Monk, BJ; Pendleton, L | 1 |
| Coleman, RL; Onstad, M; Westin, SN | 1 |
| Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J | 1 |
| Dockery, L; Moore, K; Randall, LM; Rimel, BJ | 1 |
| Estes, VM; Langelier, MF; Lee, BJ; Lin, X; Pascal, JM; Rouleau-Turcotte, É; Shao, Z; Zha, S | 1 |
| D'Este, G; Lista, F; Mattarei, A; Megighian, A; Montecucco, C; Negro, S; Rigoni, M; Stazi, M | 1 |
| Arizio, F; Bironzo, P; Listì, A; Novello, S; Passiglia, F; Righi, L; Scagliotti, GV; Volante, M | 1 |
| Barceló, IB; Benigno, B; Berton-Rigaud, D; Bessette, P; Buscema, J; de Jong, FA; du Bois, A; Dørum, A; Gupta, D; Herráez, AC; Herrstedt, J; Kalbacher, E; Lau, S; Ledermann, JA; Levy, T; Lorusso, D; Mahner, S; Matulonis, UA; Mirza, MR; Rimel, BJ; Vergote, I; Wang, P | 1 |
| Fan, Q; Li, Q; Liu, F; Ma, J; Zhang, B; Zhao, B | 1 |
| Aragón, IM; Castro, E; Cattrini, C; Cendón, Y; López-Casas, PP; Lozano, R; Olmos, D | 1 |
| Gabrail, N; Smith, C | 1 |
| Penn, CA; Walsh, CS; Wong, MS | 1 |
| Alvarez, N; Colombo, N; dePont Christensen, R; Gonzalez Martin, A; Heitz, F; Marqués, C; Meirovitz, M; Sanchez Lorenzo, L; Sanchez, J; Selle, F; van Gorp, T | 1 |
| Aoki, D; Hamanishi, J; Harano, K; Hasegawa, K; Hirasawa, T; Hori, K; Kase, Y; Komiyama, S; Kondo, E; Matsuura, M; Nakai, H; Nakamura, H; Nakamura, T; Okamoto, A; Sakata, J; Soeda, J; Sugiyama, T; Sumino, S; Suri, A; Tabata, T; Takehara, K; Takekuma, M; Yanagida, S; Yokoyama, Y | 1 |
| Belli, V; Cardone, C; Ciardiello, D; Ciardiello, F; De Falco, V; Della Corte, C; Desiderio, V; Giunta, EF; Martinelli, E; Martini, G; Matrone, N; Mele, L; Morgillo, F; Napolitano, S; Papaccio, G; Poliero, L; Selvaggi, F; Tirino, V; Troiani, T; Vitiello, PP | 1 |
| Abulizi, G; An, RF; Chen, LP; Chen, QH; Cui, H; Gao, YN; Hao, M; Hou, JM; Huang, XH; Huang, Y; Kong, BH; Li, GL; Liu, JH; Liu, ZL; Lou, G; Lu, WG; Lu, X; Mirza, MR; Tian, XF; Wang, DB; Wang, J; Wang, K; Wang, L; Wen, H; Wu, LY; Wu, XH; Yan, XJ; Yang, HY; Yang, JX; Yin, RT; Zhang, C; Zhang, Y; Zhou, Q; Zhu, JQ | 1 |
| Hamanishi, J; Hasegawa, K; Itamochi, H; Kase, Y; Matsumoto, T; Matsuura, M; Miura, K; Nagao, S; Nakai, H; Sumino, S; Suri, A; Takehara, K; Takeshima, N; Tanaka, N; Tokunaga, H; Ushijima, K; Watari, H; Yokoyama, Y | 1 |
| Grewal, K; Tabbara, IA | 1 |
| Luger, K; Roberts, G; Rudolph, J | 1 |
| Gao, H; Wang, Q; Xu, Y; Zhang, F | 1 |
| Hong, SH | 1 |
| Iwasa, S; Kase, Y; Kitano, S; Kondo, S; Koyama, T; Sato, J; Shibaki, R; Shimizu, T; Shimomura, A; Sumino, S; Suri, A; Tamura, K; Yamamoto, N; Yonemori, K | 1 |
| Alinari, L; Baiocchi, RA; Byrd, JC; Chen, TL; Harrington, B; Hertlein, E; Lehman, AM; Orlemans, E; Prouty, A; Sampath, D; Sloan, S; Truxall, J; Wasmuth, R; Woyach, JA | 1 |
| Adachi, J; Araki, M; Friboulet, L; Fujita, N; Katayama, K; Katayama, R; Kukimoto-Niino, M; Kutkowska, J; Ma, B; Maruyama, K; Mizuta, H; Nishio, M; Oh-Hara, T; Okada, K; Okuno, Y; Sagae, Y; Sasakura, Y; Shirouzu, M; Simizu, S; Takagi, S; Takemoto, A; Tamai, K; Watanabe, K; Yanagitani, N | 1 |
| Delaye, M; Rodrigues, M | 1 |
| Liu, MC; Sutedja, J; Tewari, KS | 1 |
| Aguilar-Valdés, A; Ibarra-Sánchez, MJ; Maravillas-Montero, JL; Martínez-Aguilar, J; Noriega, LG; Sosa-Hernández, VA; Tovar, AR | 1 |
| Bradic, B; Chi, KN; De Meulder, M; Espina, BM; Francis, P; Graff, JN; Hayreh, V; Hazra, A; Lattouf, JB; Mamidi, RNVS; Posadas, EM; Rezazadeh Kalebasty, A; Saad, F; Shore, ND; Yu, A; Zhu, E | 1 |
| Gao, Y; Gong, Y; Jiang, X; Li, J; Luo, Y; Xie, C; Zeng, Z; Zhang, J; Zhang, N | 1 |
| Du, X; Hu, D; Jiang, L; Luo, S; Tang, W; Tang, Y; Zhao, G; Zhao, X | 1 |
| Ai, X; Chen, G; Cui, J; Ding, C; Dong, X; Gao, B; He, J; Hu, C; Hu, X; Huang, C; Jiang, L; Li, J; Li, X; Li, Y; Liao, W; Liu, A; Liu, C; Liu, X; Liu, Z; Lu, S; Ma, Z; Pan, Y; Shi, J; Song, Y; Wang, K; Wang, M; Wang, W; Xiong, J; Yang, N; Zhang, B; Zhang, D; Zhang, H; Zhang, X; Zhang, Y; Zhao, J; Zhou, J | 1 |
| Bahar, E; Kim, DC; Kim, HS; Kim, JY; Yoon, H | 1 |
| Chen, X; Cheng, X; Dai, Z; Gu, H; Guo, W; Ni, J; Wang, Y; Xu, X; Zhao, Q; Zhou, R | 1 |
| Guo, Q; Liu, L; Lu, W; Ma, Z; Sun, X; Wang, S; You, J; Zhang, Y; Zhao, Z | 1 |
| Distel, L; Fietkau, R; Gajdošová, F; Hecht, M; Jonuscheit, S; Jost, T; Wrobel, M | 1 |
| Chan, AL; Lang, HC; Leung, JH; Lo, HF; Wang, SY | 1 |
| Adam, V; Audeh, W; Balmaña, J; Cameron, DA; Colleoni, M; Ellard, SL; Erban, J; Goldstein, LJ; Goulioti, T; Honkoop, AH; Ignatiadis, M; Jen, KY; Johannsson, OT; Juan-Fita, MJ; Kaufman, B; Láng, I; Litière, S; Macpherson, IRJ; Mailliez, A; Manso, L; Musolino, A; Poncet, C; Razis, E; Trédan, O; Tryfonidis, K; Turner, NC; Tutt, AN; Vuylsteke, P; Zoppoli, G | 1 |
| Bourdet, DL; Colley, K; Lo, A; Pfeifer, ND; Singh, D | 1 |
| Akce, M; Bacque, E; El-Khoueiry, A; Ewesuedo, R; Gupta, D; Judson, PL; Milton, A; O'Bryant, CL; Pan, P; Piha-Paul, SA; Tang, Y; Zajic, S; Zhang, ZY | 1 |
| Cai, Z; Cao, D; Chang, C; Jiang, Z; Liu, C; Mu, M; Shen, C; Yin, X; Yin, Y; Zhang, B; Zhang, L; Zhao, Z | 1 |
| Artali, R; Aviñó, A; Dallavalle, S; Eritja, R; Gargallo, R; Mattio, LM; Mazzini, S; Musso, L; Pisano, C; Princiotto, S | 1 |
| Baek, SH; Kim, BG; Lim, MC; Noh, JJ; Park, SY; Shin, W | 1 |
| Awad, MM; Dowlati, A; Dy, GK; Haque, B; Iannotti, N; Iyer Singh, N; Lu, S; Ramalingam, SS; Spigel, DR; Stinchcombe, TE; Tang, Y; Teslenko, I; Thara, E | 1 |
| Chen, L; Davidson, B; Hershman, DL; Moss, HA; Wright, JD | 1 |
| Hawkes, C; Hurteau, J; Liu, J; Maiese, EM; Spalding, C; Travers, K; Walder, L | 1 |
| Braicu, E; Carbone, V; Cibula, D; Colombo, N; Frenel, JS; Ghizzoni, V; Giolitto, S; Giudice, E; Lorusso, D; Musacchio, L; Perri, MT; Pignata, S; Ricci, C; Salutari, V; Scambia, G; Zagouri, F | 1 |
| Casey, PJ; Tang, J; Wang, M | 1 |
| Bu, H; Chu, R; Feng, J; Kong, B; Li, J; Li, X; Li, Y; Liu, L; Maurer, J; Meng, J; Pan, X; Peng, J; Song, K; Yao, S; Yuan, Z; Zhang, Q; Zhang, T | 1 |
| Lee, A | 1 |
| Bellesoeur, A; Beuzeboc, P; Diéras, V; Neuzillet, C; Rodrigues, M; Saint-Ghislain, M; Salaün, H; Stern, MH | 1 |
| Azaïs, H; Bats, AS; Bentivegna, E; Blons, H; Delanoy, N; Durdux, C; Koual, M; Laurent-Puig, P; Le Frère-Belda, MA; Le Gac, M; Nguyen-Xuan, HT; Perkins, G | 1 |
| Liu, M; Liu, T; Sun, L; Tan, S; Tang, J; Xiao, W; Zhou, X | 1 |
| Choi, MC; Jeong, DH; Kim, BG; Kim, SI; Lee, JK; Lee, JY; Lim, MC; Park, J | 1 |
| Alexandre, J; Kalbacher, E; Leary, A; Prulhière, K; Ray-Coquard, I; Selle, F | 1 |
| Guan, W; Perez, JM; Thomas, SN; Twigg, CAI | 1 |
| Agouridis, AP; Mamais, I; Michalinos, A; Pagkali, A | 1 |
| Bach, R; Pesqué, D; Pujol, RM; Recuero-Borau, J; Tormo-Mainar, S | 1 |
| Chi, KN; Danila, DC; Efstathiou, E; Espina, BM; Fizazi, K; Francis, P; George, DJ; Lara, PN; Lopez-Gitlitz, A; Mason, GE; Olmos, D; Saad, F; Sandhu, S; Scher, HI; Smith, MR; Ståhl, O; Urtishak, KA; Yu, EY; Zhao, X | 1 |
| Bessudo, A; Dezube, BJ; Duncan, M; Evilevitch, L; Gabrail, N; Guo, W; Hamilton, E; Kumar, S; Lu, S; Patel, MR; Rodon, J; Sachdev, J; Yap, TA | 1 |
| Cui, Y; Du, F; Feng, L; Huang, W; Li, B; Yin, X | 1 |
| Constantinescu, SN; Guglielmelli, P; Langmuir, P; Levy, G | 1 |
| Bohrer, J; Damle, R; Driscoll, J; Fiorella, A; Hawkins, R; Mamidi, RNVS; Manning, CD; Packman, K; Patel, S; Snyder, LA; Stratton, CF; Tatikola, K; Tryputsen, V | 1 |
| Artioli, G; Baumann, K; Bradley, WH; Calvert, PM; Dørum, A; Forget, F; Fuentes, J; González-Martín, A; Gupta, D; Hietanen, S; Kumar, A; Levy, T; Li, Y; Malinowska, IA; McCormick, C; Monk, BJ; Moore, RG; O'Cearbhaill, RE; O'Malley, DM; Pérez-Fidalgo, JA; Selle, F; Shahin, MS; Slomovitz, BM; Tusquets, I; Vulsteke, C | 1 |
| Asano, H; Enomoto, T; Ito, YM; Matsumura, N; Oda, K; Shimada, M; Watari, H; Yoshihara, K | 1 |
| Cancanelli, L; Chiumente, M; Di Spazio, L; Mengato, D; Messori, A; Rivano, M | 1 |
| Belotte, J; Clements, A; Fleming, EL; Gray, HJ; Gupta, D; Hamilton, E; Hardesty, MM; Keeton, EK; Konecny, GE; Krivak, TC; Moore, RG; Richardson, DL; Wang, P; Wright, GS | 1 |
| Feng, Y; Jia, H; Jiang, R; Jiang, W; Liu, J; Shi, T; Teng, Y; Wang, H; Wang, X; Wu, S; Xiang, L; Yu, A; Zang, R; Zhang, J; Zhang, P; Zhang, W; Zhang, Y; Zhu, J; Zhu, T; Zhu, Y | 1 |
| Ellisen, LW; Graham, JR; Hamilton, E; Han, H; Hazard, S; Irie, H; Isakoff, SJ; Liu, MC; Pan, P; Reeves, J; Santa-Maria, CA; Shan, M; Spring, LM; Tang, Y | 1 |
| González-Martín, A; Gupta, D; Korach, J; Lechpammer, S; Matulonis, UA; Mirza, MR; Monk, BJ; Moore, KN; Wu, X; York, W | 1 |
| Domchek, SM; Donze, A; Gosselin, MK; Karasic, T; Massa, R; Mick, R; O'Hara, M; Onyiah, C; Reiss, KA; Schneider, C; Teitelbaum, U; Tondon, R; Vonderheide, RH | 1 |
| Chen, X; Cheng, X; Huang, X; Ju, X; Li, J; Li, Z; Liu, F; Shou, H; Tang, J; Tang, X; Wang, H; Wen, H; Wu, X; Yang, H; Yang, J; Zhang, L; Zhang, M; Zheng, F | 1 |
| Bjartell, A; Sjöström, M | 1 |
| Ngan, RKC | 1 |
| Chen, B; Chen, J; He, A; Hou, W; Jia, M; Jiang, Z; Li, M; Miao, P; Qiu, S; Shao, Z; Shen, Y; Sun, W; Wu, X; Xu, J; Xu, X; Yuan, D; Zhang, B; Zhang, Y; Zhao, M; Zhou, Y; Zhu, T; Zhu, Y | 1 |
46 review(s) available for indazoles and piperidines
| Article | Year |
|---|---|
[Oral drugs inhibiting the VEGF pathway].
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Asthenia; Axitinib; Benzenesulfonates; Humans; Hypertension; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Proteinuria; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Early clinical studies of novel therapies for thyroid cancers.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Carcinoma; Clinical Trials as Topic; Drug Delivery Systems; Gefitinib; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Sorafenib; Thyroid Neoplasms | 2008 |
[Tumor vasculature as a therapeutic target in non-small cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Imidazoles; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Xanthones | 2008 |
Tyrosine kinase inhibitors and the thyroid.
Topics: Axitinib; Benzenesulfonates; Clinical Trials as Topic; Gefitinib; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Pharmaceutical Preparations; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins B-raf; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thyroid Gland; Thyroid Neoplasms | 2009 |
Targeted molecular therapies in thyroid carcinoma.
Topics: Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Medullary; Carcinoma, Papillary; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thyroid Neoplasms | 2009 |
Adjudin, a potential male contraceptive, exerts its effects locally in the seminiferous epithelium of mammalian testes.
Topics: Animals; Cell Adhesion; Contraceptive Agents, Male; Humans; Hydrazines; Indazoles; Indenes; Male; Piperidines; Seminiferous Epithelium; Sertoli Cells; Spermatogenesis; Spermatozoa | 2011 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
[Dermatologic side effects induced by new angiogenesis inhibitors].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Drug Eruptions; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Skin; Sorafenib; Sulfonamides; Sunitinib | 2011 |
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Benzenesulfonates; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib | 2012 |
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colorectal Neoplasms; Digestive System; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Imidazoles; Indazoles; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2012 |
[Pigmentary disorders induced by anticancer agents. Part II: targeted therapies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Dasatinib; ErbB Receptors; Humans; Imatinib Mesylate; Indazoles; Indoles; Ipilimumab; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Piperazines; Piperidines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thiazoles | 2013 |
PARP inhibitors in ovarian cancer: current status and future promise.
Topics: Antineoplastic Agents; Benzimidazoles; DNA Repair; Female; Genes, BRCA1; Genes, BRCA2; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2014 |
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Hemorrhage; Humans; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Odds Ratio; Phenylurea Compounds; Piperidines; Pyrimidines; Pyrroles; Quinazolines; Ramucirumab; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A | 2015 |
[Cancer therapy by PARP inhibitors].
Topics: Antineoplastic Agents; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; DNA Breaks, Double-Stranded; DNA Replication; DNA, Single-Stranded; Enzyme Inhibitors; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Mutation; Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Recombinational DNA Repair | 2015 |
Treatment of advanced thyroid cancer: role of molecularly targeted therapies.
Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Neuroendocrine; DNA Mutational Analysis; Drug Approval; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Molecular Targeted Therapy; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Piperidines; Proto-Oncogene Proteins c-ret; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Thyroid Neoplasms; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A | 2015 |
[Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Fatigue; Humans; Imidazoles; Indazoles; Indoles; Kidney; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2016 |
The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
Topics: Carcinoma, Ovarian Epithelial; Clinical Trials as Topic; Female; Humans; Indazoles; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2018 |
Pharmacokinetic drug evaluation of niraparib for the treatment of ovarian cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life | 2018 |
Update on PARP Inhibitors in Breast Cancer.
Topics: BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Female; Humans; Indazoles; Indoles; Neoplasm Recurrence, Local; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Progression-Free Survival | 2018 |
The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality.
Topics: Benzamides; Female; Genes, BRCA1; Genes, BRCA2; Homologous Recombination; Humans; Indazoles; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Triple Negative Breast Neoplasms | 2018 |
The role of niraparib for the treatment of ovarian cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Genes, BRCA1; Genes, BRCA2; Humans; Indazoles; Mutation; Neoplasm Recurrence, Local; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2018 |
Niraparib for the treatment of ovarian cancer.
Topics: Biomarkers, Tumor; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Practice Guidelines as Topic | 2018 |
Niraparib: A Review in Ovarian Cancer.
Topics: Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2018 |
PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; DNA Repair; Female; Genes, BRCA1; Genes, BRCA2; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Synthetic Lethal Mutations | 2019 |
Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension.
Topics: Anilides; Carcinoma, Neuroendocrine; Cardiotoxicity; Humans; Hypertension; Indazoles; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Sulfonamides; Thyroid Neoplasms | 2018 |
Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carbazoles; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Indoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Ovary; Phthalazines; Phthalimides; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2018 |
PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms.
Topics: Drug Resistance, Neoplasm; Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases | 2019 |
A decade of clinical development of PARP inhibitors in perspective.
Topics: BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Female; Genomic Instability; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors | 2019 |
Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Topics: Antineoplastic Agents; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; DNA Repair; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Indoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases | 2020 |
Latest clinical evidence of maintenance therapy in ovarian cancer.
Topics: Angiogenesis Inhibitors; Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Indoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Randomized Controlled Trials as Topic | 2020 |
Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Topics: Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival | 2020 |
Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Drug Approval; Drug Costs; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Maintenance Chemotherapy; Mutation; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Progression-Free Survival; Randomized Controlled Trials as Topic; Recombinational DNA Repair; United States; United States Food and Drug Administration | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Clinical Trials as Topic; DNA Damage; DNA Repair; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; High-Throughput Nucleotide Sequencing; Humans; Immune Checkpoint Inhibitors; Indazoles; Indoles; Male; Phthalazines; Piperazines; Piperidines; Platinum Compounds; Poly(ADP-ribose) Polymerase Inhibitors; Precision Medicine; Prognosis; Prostatic Neoplasms | 2021 |
PARP Inhibitors in Prostate Cancer.
Topics: Animals; BRCA1 Protein; BRCA2 Protein; Genetic Predisposition to Disease; Humans; Indazoles; Indoles; Male; Mutation; Neoplasm Metastasis; Phenotype; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; PTEN Phosphohydrolase; Treatment Outcome | 2021 |
Risk of pneumonitis in cancer patients treated with PARP inhibitors: A meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database.
Topics: Adverse Drug Reaction Reporting Systems; Humans; Incidence; Indazoles; Neoplasms; Phthalazines; Piperazines; Piperidines; Pneumonia; Poly(ADP-ribose) Polymerase Inhibitors; Randomized Controlled Trials as Topic; Time Factors | 2021 |
Comparative safety and tolerability of approved PARP inhibitors in cancer: A systematic review and network meta-analysis.
Topics: Humans; Indazoles; Indoles; Neoplasms; Network Meta-Analysis; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Randomized Controlled Trials as Topic | 2021 |
Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer.
Topics: Adult; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Maintenance Chemotherapy; Ovarian Neoplasms; Piperidines | 2021 |
[Homologous recombination deficiency and PARP inhibitors in therapeutics].
Topics: Breast Neoplasms; DNA Damage; DNA Repair-Deficiency Disorders; Drug Resistance, Neoplasm; Female; Genes, BRCA1; Genes, BRCA2; Homologous Recombination; Humans; Indazoles; Indoles; Male; Ovarian Neoplasms; Pancreatic Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; Recombinational DNA Repair | 2022 |
[Place of PARP inhibitors in the treatment of endometrial and cervical cancers].
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Clinical Trials as Topic; DNA Damage; DNA Repair-Deficiency Disorders; Endometrial Neoplasms; Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Papillomavirus Infections; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Uterine Cervical Neoplasms | 2022 |
Traitement médical de première ligne du cancer épithélial de l'ovaire de haut grade: First-line medical treatment of high-grade epithelial ovarian cancer.
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Genes, BRCA1; Genes, BRCA2; Humans; Indazoles; Maintenance Chemotherapy; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2021 |
Safety Profile of Niraparib as Maintenance Therapy for Ovarian Cancer: A Systematic Review and Meta-Analysis.
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines | 2022 |
JAK inhibitors and COVID-19.
Topics: Antiviral Agents; Azetidines; COVID-19 Drug Treatment; Cytokines; Humans; Imidazoles; Indazoles; Janus Kinase Inhibitors; Piperidines; SARS-CoV-2 | 2022 |
Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052).
Topics: Clinical Trials, Phase II as Topic; Female; Genital Neoplasms, Female; Homologous Recombination; Humans; Indazoles; Ovarian Neoplasms; Piperidines | 2022 |
Niraparib treatment for patients with
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life | 2022 |
First-line maintenance therapy with niraparib in advanced platinum-sensitive ovarian cancer: two 'long responder' case reports and review of the current literature.
Topics: Asian People; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines | 2023 |
36 trial(s) available for indazoles and piperidines
| Article | Year |
|---|---|
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
Topics: Adult; Aged; BRCA1 Protein; BRCA2 Protein; Cohort Studies; Female; Follow-Up Studies; Heterozygote; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasms; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Prostatic Neoplasms; Tissue Distribution | 2013 |
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Disease-Free Survival; Double-Blind Method; Female; Genes, BRCA1; Germ-Line Mutation; Homologous Recombination; Humans; Indazoles; Kaplan-Meier Estimate; Maintenance Chemotherapy; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Piperidines; Platinum Compounds; Young Adult | 2016 |
Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Biological Availability; Breast Neoplasms; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Radioactive Tracers; Tandem Mass Spectrometry | 2018 |
Safety and dose modification for patients receiving niraparib.
Topics: Administration, Oral; Adult; Body Weight; Dose-Response Relationship, Drug; Female; Humans; Incidence; Indazoles; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Platelet Count; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Retrospective Studies; Risk Factors; Thrombocytopenia | 2018 |
Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Double-Blind Method; Female; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Patient Reported Outcome Measures; Piperidines; Progression-Free Survival; Quality of Life; Surveys and Questionnaires | 2018 |
Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Patient Reported Outcome Measures; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2019 |
Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
Topics: Aged; Carcinoma, Ovarian Epithelial; Cardiotoxicity; Double-Blind Method; Electrocardiography; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Long QT Syndrome; Middle Aged; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2019 |
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Topics: Adolescent; Adult; Aged; BRCA1 Protein; BRCA2 Protein; Canada; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Middle Aged; Mutation; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Time Factors; United States; Young Adult | 2019 |
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Class I Phosphatidylinositol 3-Kinases; Female; GTP Phosphohydrolases; Humans; Indazoles; Male; Membrane Proteins; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Sulfonamides; Treatment Outcome; Young Adult | 2020 |
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival | 2019 |
A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Indazoles; Middle Aged; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival | 2019 |
Phase I Pharmacokinetic Study of Niraparib in Chinese Patients with Epithelial Ovarian Cancer.
Topics: Female; Humans; Indazoles; Male; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2020 |
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Topics: Aged; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Endometrioid; Disease Progression; Female; Humans; Hypertension; Indazoles; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Progression-Free Survival; Proteinuria; Thrombocytopenia | 2019 |
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Double-Blind Method; Female; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Nausea; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Quality of Life; Survival Analysis | 2019 |
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; CD8-Positive T-Lymphocytes; DNA Mutational Analysis; Drug Monitoring; Female; Gene Amplification; Humans; Indazoles; Interferons; Macrophages; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Ovary; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Programmed Cell Death 1 Ligand 2 Protein; Programmed Cell Death 1 Receptor; Recombinational DNA Repair; Single-Cell Analysis; Treatment Outcome; Tumor Microenvironment | 2020 |
A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study.
Topics: Adolescent; China; Cytoreduction Surgical Procedures; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Positron Emission Tomography Computed Tomography; Quality of Life | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rati
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; DNA Repair Enzymes; Germ-Line Mutation; Humans; Indazoles; Lung Neoplasms; Mesothelioma, Malignant; Mutation; Piperidines; Pleural Neoplasms; Prognosis; Prospective Studies | 2021 |
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
Topics: Carcinoma, Ovarian Epithelial; Double-Blind Method; Female; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival | 2020 |
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Double-Blind Method; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Peritoneal Neoplasms; Piperidines; Platinum; Progression-Free Survival; Time Factors | 2021 |
Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer.
Topics: Female; Homologous Recombination; Humans; Indazoles; Japan; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2021 |
Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; China; Double-Blind Method; Female; Humans; Indazoles; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2021 |
Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer.
Topics: Female; Humans; Indazoles; Japan; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines | 2021 |
The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study.
Topics: Adult; Aged; Cohort Studies; Female; Humans; Indazoles; Japan; Male; Middle Aged; Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2021 |
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE).
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Humans; Indazoles; Male; Middle Aged; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Prednisone; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Thiohydantoins | 2021 |
Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Indazoles; Lung Neoplasms; Maintenance Chemotherapy; Ovarian Neoplasms; Piperidines | 2021 |
Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID-19.
Topics: Administration, Inhalation; Adult; Area Under Curve; Azetidines; COVID-19 Drug Treatment; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Healthy Volunteers; Humans; Imidazoles; Indazoles; Killer Cells, Natural; Lymphocyte Count; Male; Middle Aged; Piperidines; Young Adult | 2021 |
Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment.
Topics: Aged; Area Under Curve; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Liver; Male; Middle Aged; Piperidines | 2021 |
JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Indazoles; Lung Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2022 |
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Immune Checkpoint Inhibitors; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2021 |
A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Republic of Korea | 2022 |
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.
Topics: Adolescent; Adult; Androgen Antagonists; Androgens; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; DNA Repair; Humans; Indazoles; Male; Piperidines; Prostatic Neoplasms, Castration-Resistant; Thrombocytopenia | 2022 |
IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Humans; Indazoles; Neoplasms; Paclitaxel; Piperidines; Vascular Endothelial Growth Factor A | 2022 |
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study.
Topics: Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Female; Humans; Indazoles; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Piperidines | 2022 |
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Humans; Indazoles; Maintenance Chemotherapy; Ovarian Neoplasms; Piperidines; Platinum | 2022 |
Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Hypertension; Immune Checkpoint Inhibitors; Indazoles; Ipilimumab; Nivolumab; Pancreatic Neoplasms; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors | 2022 |
166 other study(ies) available for indazoles and piperidines
| Article | Year |
|---|---|
[Azoles. 4. The properties of 3-bromo- and 3-iodoindazole].
Topics: Chemical Phenomena; Chemistry; Hydrazines; Indazoles; Morpholines; Piperidines; Pyrazoles; Temperature | 1978 |
[Azoles. 3. Nitro derivatives of 3-chlorindazoles and the influence of C-5, C-6 and N-nitrogroups on the reaction capability of C-3 chlorine atoms].
Topics: Acetylation; Chemical Phenomena; Chemistry; Chlorine; Hydrolysis; Indazoles; Isomerism; Morpholines; Nitro Compounds; Piperidines; Pyrazoles; Pyrrolidines; Temperature | 1978 |
[Persistence of the control of the fluctuations of heart rate in the anesthetized and pithed adult rat. Effect of enteraminergic drugs].
Topics: Anesthesia; Animals; Decerebrate State; Depression, Chemical; Dose-Response Relationship, Drug; Ether; Female; Granisetron; Heart Rate; Indazoles; Male; Piperidines; Rats; Ritanserin; Serotonin Antagonists | 1991 |
Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties.
Topics: Animals; Antiemetics; Binding, Competitive; Cerebral Cortex; Cisplatin; Dose-Response Relationship, Drug; Ferrets; Fluoxetine; Granisetron; Indazoles; Male; Piperidines; Quipazine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Vomiting | 1993 |
LY353433, a potent, orally effective, long-acting 5-HT(4) receptor antagonist: comparison to cisapride and RS23597-190.
Topics: Adamantane; Administration, Oral; Aminobenzoates; Animals; Cisapride; Esophagus; Female; In Vitro Techniques; Indazoles; Male; Muscle Relaxation; para-Aminobenzoates; Piperidines; Rats; Rats, Inbred F344; Rats, Sprague-Dawley; Rats, Wistar; Serotonin Antagonists | 1996 |
Neuroprotective effects of 7-nitroindazole in the gerbil model of global cerebral ischaemia.
Topics: Animals; Brain Ischemia; Disease Models, Animal; Dizocilpine Maleate; Enzyme Inhibitors; Gerbillinae; Indazoles; Male; Neuroprotective Agents; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Piperidines; Quinoxalines | 1996 |
New 2-piperazinylbenzimidazole derivatives as 5-HT3 antagonists. Synthesis and pharmacological evaluation.
Topics: Animals; Benzimidazoles; Guinea Pigs; Indazoles; Male; Models, Chemical; Piperazines; Piperidines; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Receptors, Serotonin, 5-HT3; Receptors, Serotonin, 5-HT4; Serotonin Antagonists; Tropanes | 1997 |
Nitric oxide synthase inhibitors attenuate phencyclidine-induced disruption of prepulse inhibition.
Topics: Acoustic Stimulation; Animals; Biguanides; Biogenic Polyamines; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Indazoles; Inhibition, Psychological; Male; Nitric Oxide Synthase; Nitroarginine; Phencyclidine; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Reflex, Startle | 1998 |
Propulsion in guinea pig colon induced by 5-hydroxytryptamine (HT) via 5-HT4 and 5-HT3 receptors.
Topics: Animals; Benzofurans; Colon; Gastrointestinal Motility; Guinea Pigs; Humans; In Vitro Techniques; Indazoles; Indoles; Male; Piperidines; Rats; Receptors, Serotonin; Receptors, Serotonin, 5-HT3; Receptors, Serotonin, 5-HT4; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Sulfonamides; Tropanes | 1999 |
Contribution of nitric oxide to the presynaptic inhibition by endothelin ETB receptor of the canine stellate ganglionic transmission.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Acetylcholine; Animals; Antihypertensive Agents; Dogs; Endothelin Receptor Antagonists; Enzyme Inhibitors; Female; In Vitro Techniques; Indazoles; Male; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Oligopeptides; Oxadiazoles; Piperidines; Quinoxalines; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin; Stellate Ganglion; Sulfonamides; Synapses; Synaptic Transmission | 1999 |
Role of ET(B) receptors and nitric oxide in adrenal catecholamine secretion in anesthetized dogs.
Topics: Acetylcholine; Adrenal Glands; Animals; Dogs; Electric Stimulation; Endothelin Receptor Antagonists; Enzyme Inhibitors; Epinephrine; Female; Indazoles; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Norepinephrine; Oligopeptides; Piperidines; Receptor, Endothelin B; Receptors, Endothelin; Splanchnic Nerves; Viper Venoms | 1999 |
Endogenous cannabinoid, anandamide, acts as a noncompetitive inhibitor on 5-HT3 receptor-mediated responses in Xenopus oocytes.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Analysis of Variance; Animals; Arachidonic Acids; Biguanides; Cannabinoids; Chelating Agents; Cyclic AMP; Dose-Response Relationship, Drug; Drug Interactions; Egtazic Acid; Electrophysiology; Endocannabinoids; Enzyme Inhibitors; Female; Indazoles; Membrane Potentials; Oocytes; Pertussis Toxin; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Receptors, Serotonin, 5-HT3; Rimonabant; RNA, Complementary; Serotonin; Serotonin 5-HT3 Receptor Antagonists; Serotonin Receptor Agonists; Thionucleotides; Tropanes; Xenopus laevis | 2002 |
Thrombin inhibits NMDA-mediated nociceptive activity in the mouse: possible mediation by endothelin.
Topics: Acetic Acid; Amino Acid Chloromethyl Ketones; Animals; Behavior, Animal; Capillary Permeability; Endothelins; Evans Blue; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Hyperalgesia; Indazoles; Injections, Intraperitoneal; Male; Mice; N-Methylaspartate; Nociceptors; Oligopeptides; Pain Measurement; Peptide Fragments; Peptides, Cyclic; Physical Stimulation; Piperidines; Reaction Time; Receptor, Endothelin A; Receptor, Endothelin B; Thrombin; Urea | 2003 |
Behavioral effects of NMDA receptor agonists and antagonists in combination with nitric oxide-related compounds.
Topics: 2-Amino-5-phosphonovalerate; Animals; Arginine; Conditioning, Operant; Dizocilpine Maleate; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Gallic Acid; Guanidines; Indazoles; Injections, Intraperitoneal; Kynurenic Acid; Molsidomine; N-Methylaspartate; NG-Nitroarginine Methyl Ester; Nitric Oxide Donors; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitroprusside; Phencyclidine; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate | 2003 |
ACYLTRYPTAMINES. II. SYNTHESIS OF ACYLTRYPTAMINES, INDAZOLES, AND AZEPINOINDOLES FROM THE ACYLPHENYLHYDRAZONES OF 2,3-PIPERIDINEDIONE.
Topics: Antihypertensive Agents; Blood Pressure; Chemistry, Pharmaceutical; Dogs; Heterocyclic Compounds; Indazoles; Indoles; Mice; Pharmacology; Piperidines; Research; Seizures; Selective Serotonin Reuptake Inhibitors; Serotonin; Toxicology; Tryptamines | 1963 |
Tricyclic pyrazoles. Part 2: Synthesis and biological evaluation of novel 4,5-dihydro-1H-benzo[g]indazole-based ligands for cannabinoid receptors.
Topics: Animals; Cannabinoid Receptor Antagonists; Gastrointestinal Transit; Indazoles; Ligands; Mice; Mice, Inbred ICR; Molecular Structure; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant; Structure-Activity Relationship | 2005 |
Involvement of nitric oxide pathways in short term modulation of tyrosine hydroxylase activity by endothelins 1 and 3 in the rat anterior hypothalamus.
Topics: Animals; Carbazoles; Cyclic GMP; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Endothelin-3; Hypothalamus, Anterior; Indazoles; Indoles; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type I; Nitroprusside; Oligopeptides; Oxadiazoles; Piperidines; Quinoxalines; Rats; Suramin; Tyrosine 3-Monooxygenase | 2005 |
Combined effects of mechanical and ischemic injury to cortical cells: secondary ischemia increases damage and decreases effects of neuroprotective agents.
Topics: Animals; Brain Ischemia; Cell Count; Cell Survival; Cells, Cultured; Cerebral Cortex; Enzyme Inhibitors; Immunohistochemistry; Indazoles; Mice; Mitogen-Activated Protein Kinase 1; Neurons; Neuroprotective Agents; Nitric Oxide Synthase Type I; Physical Stimulation; Piperidines; Stress, Mechanical; Superoxide Dismutase; Thiazoles | 2005 |
Aminopiperidine indazoles as orally efficacious melanin concentrating hormone receptor-1 antagonists.
Topics: Administration, Oral; Animals; Anti-Obesity Agents; Humans; Indazoles; Mice; Piperidines; Receptors, Somatostatin; Tissue Distribution | 2005 |
Screening for cardiovascular safety: a structure-activity approach for guiding lead selection of melanin concentrating hormone receptor 1 antagonists.
Topics: Animals; Anti-Obesity Agents; Blood Pressure; Brain; Cardiovascular System; Cell Line, Tumor; Chromones; Dogs; Indazoles; Male; Mice; Mice, Inbred C57BL; Myocardial Contraction; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, Somatostatin; Structure-Activity Relationship; Tissue Distribution | 2006 |
Lack of efficacy of melanin-concentrating hormone-1 receptor antagonists in models of depression and anxiety.
Topics: Analysis of Variance; Animals; Anxiety; Benzopyrans; Biphenyl Compounds; Conflict, Psychological; Depressive Disorder; Disease Models, Animal; Hindlimb Suspension; Indazoles; Male; Mice; Mice, Inbred BALB C; Motor Activity; Naphthalenes; Piperidines; Pyrimidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Somatostatin; Swimming | 2006 |
Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.
Topics: Animals; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Stability; Humans; Indazoles; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Pharmaceutical Preparations; Pharmacokinetics; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Rats; rho-Associated Kinases; Structure-Activity Relationship | 2007 |
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Biomedical Research; Breast Neoplasms; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Molecular Structure; Neoplasms; Organoplatinum Compounds; Pancreatic Neoplasms; Piperidines; Prednisolone; Prostatic Neoplasms; Quinazolines; Treatment Outcome | 2007 |
Role of nitric oxide in regulation of retinal blood flow in response to hyperoxia in cats.
Topics: Animals; Antihypertensive Agents; Blood Flow Velocity; Blood Pressure; Cats; Enzyme Inhibitors; Female; Heart Rate; Hydrogen-Ion Concentration; Hyperoxia; Indazoles; Injections; Laser-Doppler Flowmetry; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Oligopeptides; Oxygen; Partial Pressure; Peptides, Cyclic; Piperidines; Regional Blood Flow; Retinal Vessels; Vitreous Body | 2008 |
Pharmacological properties and discriminative stimulus effects of a novel and selective 5-HT2 receptor agonist AL-38022A [(S)-2-(8,9-dihydro-7H-pyrano[2,3-g]indazol-1-yl)-1-methylethylamine].
Topics: Adrenergic beta-2 Receptor Agonists; Animals; Benzopyrans; Calcium Signaling; Chemistry, Physical; Cloning, Molecular; Cyclic AMP; Discrimination, Psychological; DOM 2,5-Dimethoxy-4-Methylamphetamine; Dose-Response Relationship, Drug; Drug Stability; Fluorobenzenes; Humans; In Vitro Techniques; Indazoles; Macaca mulatta; Male; Piperidines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Agonists; Serotonin Antagonists; Serotonin Receptor Agonists; Stomach | 2009 |
Identification of a novel series of 3-piperidinyl-5-sulfonylindazoles as potent 5-HT6 ligands.
Topics: Cognition Disorders; Dementia; Humans; Indazoles; Ligands; Piperidines; Receptors, Serotonin; Serotonin Antagonists; Sulfinic Acids | 2009 |
Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors.
Topics: Administration, Oral; Amides; Animals; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Drug Discovery; Drug Stability; Enzyme Inhibitors; Female; Genes, BRCA1; Genes, BRCA2; Humans; Indazoles; Inhibitory Concentration 50; Mutation; Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Rats | 2009 |
Electron density guided fragment-based lead discovery of ketohexokinase inhibitors.
Topics: Animals; Caco-2 Cells; Cell Membrane Permeability; Crystallography, X-Ray; Electrons; Fructokinases; Humans; In Vitro Techniques; Indazoles; Male; Microsomes, Liver; Models, Molecular; Molecular Structure; Piperidines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2010 |
Involvement of spinal NR2B-containing NMDA receptors in oxaliplatin-induced mechanical allodynia in rats.
Topics: Animals; Dizocilpine Maleate; Enzyme Inhibitors; Gene Expression Regulation; Hyperalgesia; Indazoles; Male; Memantine; Neurons; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Organoplatinum Compounds; Oxaliplatin; Phenols; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Spinal Cord | 2011 |
Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Crystallography, X-Ray; Drug Screening Assays, Antitumor; Indazoles; Mice; Mice, SCID; Models, Molecular; Molecular Structure; Morpholines; Neoplasm Transplantation; Phosphorylation; Piperidines; Protein Binding; Protein Serine-Threonine Kinases; Pyrimidines; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Stereoisomerism; Structure-Activity Relationship; Transplantation, Heterologous | 2011 |
The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.
Topics: Anilides; Axitinib; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Indazoles; Indoles; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sunitinib; Thyroid Gland; Tumor Cells, Cultured | 2011 |
Neuronal NR2B-containing NMDA receptor mediates spinal astrocytic c-Jun N-terminal kinase activation in a rat model of neuropathic pain.
Topics: Animals; Astrocytes; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Guanylate Cyclase; Hyperalgesia; Indazoles; JNK Mitogen-Activated Protein Kinases; Male; Neuralgia; Neurons; Nitric Oxide Synthase Type I; Pain Measurement; Phenols; Phosphorylation; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Signal Transduction; Spinal Cord | 2011 |
MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Chemoradiotherapy; Female; Humans; Indazoles; Lung Neoplasms; Mice; Mice, Nude; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Drug approvals 2011: focus on companion diagnostics.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Biomarkers, Tumor; Brentuximab Vedotin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crizotinib; Drug Approval; Female; Humans; Imidazoles; Immunoconjugates; Indazoles; Indoles; Ipilimumab; Lung Neoplasms; Male; Melanoma; Molecular Targeted Therapy; Neoplasms; Piperidines; Prostatic Neoplasms; Pyrazoles; Pyridines; Quinazolines; Rare Diseases; Sulfonamides; Survival Analysis; United States; United States Food and Drug Administration; Vemurafenib | 2012 |
Synthesis of 7-oxo-dihydrospiro[indazole-5,4'-piperidine] acetyl-CoA carboxylase inhibitors.
Topics: Acetyl-CoA Carboxylase; Alkenes; Alkylation; Chemistry Techniques, Synthetic; Enzyme Inhibitors; Indazoles; Ketones; Piperidines; Pyrazoles; Stereoisomerism; Substrate Specificity | 2012 |
Regioselective zincation of indazoles using TMP2Zn and Negishi cross-coupling with aryl and heteroaryl iodides.
Topics: Catalysis; Indazoles; Iodides; Palladium; Piperidines; Stereoisomerism; Zinc | 2012 |
NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile.
Topics: Analysis of Variance; Animals; Anti-Obesity Agents; Blood Glucose; Body Mass Index; Body Weight; Brain-Derived Neurotrophic Factor; Cannabinoid Receptor Antagonists; Cholesterol; Dietary Fats; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Gene Expression Regulation; Hypothalamus; Indazoles; Intra-Abdominal Fat; Liver; Male; Mice; Mice, Inbred C57BL; Nerve Growth Factor; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Serotonin Plasma Membrane Transport Proteins; Thiophenes; Transaminases; Triglycerides | 2012 |
PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Female; Indazoles; MAP Kinase Kinase 1; Melanoma; Mice; Mice, Nude; Models, Biological; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Sulfonamides; Xenograft Model Antitumor Assays | 2013 |
The anticancer agent YC-1 suppresses progestin-stimulated VEGF in breast cancer cells and arrests breast tumor development.
Topics: Animals; Anthracenes; Apoptosis; Blotting, Western; Cell Proliferation; Enzyme Activators; Enzyme-Linked Immunosorbent Assay; Female; Guanylate Cyclase; Hormone Antagonists; Humans; Immunoenzyme Techniques; Indazoles; Mammary Neoplasms, Animal; Mice; Mice, Nude; Mifepristone; Piperidines; Progestins; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2013 |
Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma.
Topics: Animals; Caspase 3; Cell Line, Tumor; Chemoradiotherapy; Enzyme Inhibitors; Female; Histones; Humans; Indazoles; Mice; Neoplasm Metastasis; Neuroblastoma; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Radiation-Sensitizing Agents | 2013 |
PARP inhibitors: pitfalls and promises.
Topics: BRCA1 Protein; BRCA2 Protein; Female; Humans; Indazoles; Male; Mutation; Neoplasm Recurrence, Local; Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2013 |
A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; DNA Breaks, Double-Stranded; DNA Repair; DNA-Binding Proteins; Endonucleases; Enzyme Inhibitors; G2 Phase Cell Cycle Checkpoints; High-Throughput Screening Assays; Humans; Indazoles; Lung Neoplasms; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Isoforms; Rad51 Recombinase; RNA Interference; RNA, Small Interfering | 2013 |
Phosphoproteomic characterization of DNA damage response in melanoma cells following MEK/PI3K dual inhibition.
Topics: Azetidines; Blotting, Western; Cell Line, Tumor; Chromatography, Liquid; DNA Damage; Humans; Indazoles; Linear Models; Melanoma; Mitogen-Activated Protein Kinase Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphoproteins; Phosphorylation; Piperidines; Proteomics; Signal Transduction; Sulfonamides; Tandem Mass Spectrometry | 2013 |
Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells.
Topics: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Cell Survival; DNA Breaks, Double-Stranded; DNA Breaks, Single-Stranded; DNA Repair; Female; Histones; Humans; Hydrogen Peroxide; Indazoles; Lung Neoplasms; Male; Microscopy, Fluorescence; Oxidants; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Rad51 Recombinase; Radiation-Sensitizing Agents; Tumor Stem Cell Assay; Tumor Suppressor Protein p53 | 2014 |
Development of a highly potent, novel M5 positive allosteric modulator (PAM) demonstrating CNS exposure: 1-((1H-indazol-5-yl)sulfoneyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (ML380).
Topics: Allosteric Regulation; Animals; Central Nervous System; Drug Discovery; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Humans; Indazoles; Male; Piperidines; Rats; Receptor, Muscarinic M5; Substrate Specificity; Sulfonamides | 2014 |
Possible involvement of GABAergic and nitriergic systems for antianxiety-like activity of piperine in unstressed and stressed mice.
Topics: Alkaloids; Animals; Anti-Anxiety Agents; Anxiety; Benzodioxoles; Diazepam; Disease Models, Animal; Dose-Response Relationship, Drug; gamma-Aminobutyric Acid; Guanidines; Indazoles; Male; Maze Learning; Mice; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type II; Nitrites; Piperidines; Polyunsaturated Alkamides; Stress, Psychological | 2014 |
Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Indazoles; MAP Kinase Kinase 1; Mice; Models, Biological; Mutation; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Standard of Care; Sulfonamides; Xenograft Model Antitumor Assays | 2015 |
Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination.
Topics: Animals; BRCA1 Protein; BRCA2 Protein; Drug Discovery; Enzyme Inhibitors; Homologous Recombination; Humans; Indazoles; Models, Molecular; Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases | 2015 |
Immunoaffinity enrichment coupled to quantitative mass spectrometry reveals ubiquitin-mediated signaling events.
Topics: Apoptosis; Azetidines; Cell Line, Tumor; DNA Damage; Enzyme Inhibitors; Humans; Indazoles; Interleukin-17; Intracellular Signaling Peptides and Proteins; MAP Kinase Kinase Kinases; Mitochondrial Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Proteins; Proteomics; Signal Transduction; Sulfonamides; Tandem Mass Spectrometry; Transcription Factors; Ubiquitin; Ubiquitin-Protein Ligases; Ubiquitination | 2015 |
Cannabinoid and nitric oxide signaling interplay in the modulation of hippocampal hyperexcitability: Study on electrophysiological and behavioral models of temporal lobe epilepsy in the rat.
Topics: Animals; Benzoxazines; Cannabinoid Receptor Agonists; Cannabinoids; Disease Models, Animal; Dose-Response Relationship, Drug; Epilepsy, Temporal Lobe; Hippocampus; Indazoles; Male; Morpholines; Naphthalenes; Nitric Oxide; Nitric Oxide Synthase; Pilocarpine; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1 | 2015 |
Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
Topics: Animals; Antineoplastic Agents, Alkylating; Benzimidazoles; Cell Line; Cell Line, Tumor; DNA Damage; DNA Repair; DNA-Binding Proteins; Drug Tolerance; Humans; Indazoles; Mice; Neoplasms, Experimental; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases | 2015 |
Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.
Topics: Animals; Astrocytoma; Benzimidazoles; Blotting, Western; Brain Stem Neoplasms; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Child; Combined Modality Therapy; Glioma; Humans; Indazoles; Kaplan-Meier Estimate; Linear Models; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Microscopy, Confocal; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Pons; Radiotherapy; Xenograft Model Antitumor Assays | 2015 |
Native CB1 receptor affinity, intrinsic activity and accumbens shell dopamine stimulant properties of third generation SPICE/K2 cannabinoids: BB-22, 5F-PB-22, 5F-AKB-48 and STS-135.
Topics: Adamantane; Animals; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Central Nervous System Stimulants; Dopamine Agents; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Indazoles; Indoles; Male; Mice, Inbred C57BL; Mice, Knockout; Molecular Structure; Naphthalenes; Nucleus Accumbens; Piperidines; Prefrontal Cortex; Pyrazoles; Quinolines; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1 | 2016 |
Synthesis and SAR of calcitonin gene-related peptide (CGRP) antagonists containing substituted aryl-piperazines and piperidines.
Topics: Calcitonin Gene-Related Peptide; Cell Line, Tumor; Cell Membrane Permeability; Humans; Indazoles; Inhibitory Concentration 50; Piperazine; Piperazines; Piperidines; Quinazolinones; Structure-Activity Relationship | 2016 |
The Chemokine CCL2 Mediates the Seizure-enhancing Effects of Systemic Inflammation.
Topics: Animals; Antibodies; Benzoxazines; Chemokine CCL2; Disease Models, Animal; Electroencephalography; Epilepsy, Temporal Lobe; Excitatory Amino Acid Agonists; Hippocampus; Indazoles; Inflammation; Kainic Acid; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; Piperidines; Propionates; Receptors, CCR2; RNA, Messenger; Signal Transduction; Up-Regulation | 2016 |
PARPs pick-up.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Drug Industry; Humans; Indazoles; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2016 |
Effect of the novel synthetic cannabinoids AKB48 and 5F-AKB48 on "tetrad", sensorimotor, neurological and neurochemical responses in mice. In vitro and in vivo pharmacological studies.
Topics: Adamantane; Aggression; Animals; Behavior, Animal; Binding, Competitive; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Cannabis; Catalepsy; Dopamine; Dronabinol; Humans; In Vitro Techniques; Indazoles; Indoles; Male; Mice; Motor Activity; Naphthalenes; Nucleus Accumbens; Pain Threshold; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Reflex, Abnormal; Seizures | 2016 |
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.
Topics: DNA-Binding Proteins; Female; Genes, BRCA2; Homologous Recombination; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Promoter Regions, Genetic | 2016 |
In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC.
Topics: A549 Cells; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azetidines; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Synergism; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Lung Neoplasms; Male; MAP Kinase Kinase Kinases; Middle Aged; Molecular Targeted Therapy; Mutation; Piperidines; Protein Kinase Inhibitors; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases | 2016 |
Niraparib Slows Ovarian Cancer Progression.
Topics: BRCA1 Protein; BRCA2 Protein; Clinical Trials, Phase III as Topic; Disease Progression; Female; Germ-Line Mutation; Humans; Indazoles; Maintenance Chemotherapy; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Treatment Outcome | 2016 |
Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine.
Topics: Chromatography, High Pressure Liquid; Humans; Indazoles; Limit of Detection; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Tandem Mass Spectrometry | 2017 |
[Molecular mechanism of gastrointestinal stromal tumors and progress in drug research].
Topics: Benzimidazoles; Exons; Gastrointestinal Stromal Tumors; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Indazoles; Mutation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; Quinolones; Succinate Dehydrogenase; Sulfonamides | 2016 |
Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Consciousness; Hemodynamics; Indazoles; Losartan; Male; Niacinamide; Phenylurea Compounds; Piperidines; Propranolol; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Regional Blood Flow; Sorafenib; Sulfonamides | 2017 |
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
Topics: Animals; Benzimidazoles; Enzyme Inhibitors; HEK293 Cells; Humans; Indazoles; Models, Molecular; Phenanthrenes; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Tankyrases | 2017 |
The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cerebellar Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Humans; Indazoles; Medulloblastoma; Molecular Targeted Therapy; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sulfonamides | 2017 |
Niraparib: First Global Approval.
Topics: Adult; Carcinoma, Ovarian Epithelial; Double-Blind Method; Drug Approval; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration | 2017 |
Fatal intoxication by 5F-ADB and diphenidine: Detection, quantification, and investigation of their main metabolic pathways in humans by LC/MS/MS and LC/Q-TOFMS.
Topics: Cannabinoids; Chromatography, Liquid; Humans; Indazoles; Japan; Metabolic Networks and Pathways; Piperidines; Psychotropic Drugs; Receptor, Cannabinoid, CB1; Tandem Mass Spectrometry; Urinalysis | 2018 |
[Il ruolo di niraparib nel trattamento del carcinoma ovarico: attualità e prospettive.]
Topics: Antineoplastic Agents; Disease-Free Survival; DNA Breaks, Double-Stranded; DNA Repair; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2017 |
Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.
Topics: Cell Line, Tumor; Clone Cells; DNA Repair; Humans; Indazoles; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mutation; Phthalazines; Piperazines; Piperidines; Pleural Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Synthetic Lethal Mutations; Tumor Suppressor Proteins; Ubiquitin Thiolesterase | 2017 |
Survival of pancreatic cancer cells lacking KRAS function.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Carcinoma, Pancreatic Ductal; DNA Copy Number Variations; Humans; Immunoblotting; Indazoles; Mice; Morpholines; Pancreatic Neoplasms; Phenylurea Compounds; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins p21(ras); Purines; Pyrimidines; Pyrimidinones; Quinazolinones; Sulfonamides; Thiazoles | 2017 |
PARP inhibitors for ovarian cancer.
Topics: Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Treatment Outcome | 2017 |
The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer.
Topics: Adult; Aged; Area Under Curve; Dietary Fats; Drug Monitoring; Fasting; Female; Food-Drug Interactions; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Therapeutic Equivalency | 2018 |
The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Quinolines | 2018 |
Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.
Topics: Administration, Oral; Antineoplastic Agents; Azetidines; Child; Chromatography, High Pressure Liquid; Humans; Imidazoles; Indazoles; Indoles; Limit of Detection; Linear Models; Oximes; Phenylurea Compounds; Piperidines; Pyridines; Pyridones; Pyrimidines; Pyrimidinones; Reproducibility of Results; Sulfonamides; Tandem Mass Spectrometry; Vemurafenib | 2018 |
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy.
Topics: Aged; BRCA1 Protein; BRCA2 Protein; Clinical Trials as Topic; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Female; Germ-Line Mutation; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Progression-Free Survival; Risk Assessment | 2018 |
PARPi related toxicities: do we need more appropriate instruments to evaluate it?
Topics: Humans; Indazoles; Piperidines | 2018 |
The evolution of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Capecitabine; Female; Furans; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Indoles; Ketones; Mutation; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Vinblastine; Vinorelbine | 2018 |
PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey.
Topics: Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors | 2018 |
Valproate augments Niraparib killing of tumor cells.
Topics: Animals; Autophagy; Biomarkers; Cell Line, Tumor; Cell Survival; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Gene Knockdown Techniques; Humans; Indazoles; Mice; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Signal Transduction; Valproic Acid | 2018 |
Cyclooxygenase inhibitors potentiate receptor tyrosine kinase therapies in bladder cancer cells in vitro.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Axitinib; Benzamides; Caspases; Cell Line, Tumor; Cell Survival; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Dogs; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imidazoles; Indazoles; Indomethacin; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Pyridines; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Thiazoles; Urinary Bladder Neoplasms | 2018 |
PARP inhibitors and quality of life in ovarian cancer.
Topics: Double-Blind Method; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life | 2018 |
Using PARP Inhibitors in Advanced Ovarian Cancer.
Topics: Anemia; Creatinine; Drug Administration Schedule; Drug Interactions; Exanthema; Fatigue; Female; Genes, BRCA1; Genes, BRCA2; Heart Rate; Humans; Hypertension; Indazoles; Leukopenia; Mutation; Myelodysplastic Syndromes; Nasopharyngitis; Nausea; Ovarian Neoplasms; Piperidines; Pneumonia; Poly(ADP-ribose) Polymerase Inhibitors; Thrombocytopenia; Transaminases; Vomiting | 2018 |
Determination of interactions between human serum albumin and niraparib through multi-spectroscopic and computational methods.
Topics: Humans; Indazoles; Molecular Docking Simulation; Piperidines; Protein Binding; Serum Albumin, Human; Spectrometry, Fluorescence; Static Electricity | 2019 |
Niraparib - A promising drug with hematological toxicity.
Topics: Aged, 80 and over; Female; Hematologic Diseases; Humans; Indazoles; Middle Aged; Mutation; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2019 |
Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma
Topics: Apoptosis; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cell Cycle; Cell Line, Tumor; Chemoprevention; CRISPR-Cas Systems; DNA Breaks, Double-Stranded; DNA Repair; Female; Germ-Line Mutation; HeLa Cells; Humans; Indazoles; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Spheroids, Cellular; Synthetic Lethal Mutations; X-ray Repair Cross Complementing Protein 1 | 2018 |
Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts.
Topics: Antineoplastic Agents; Cell Line, Tumor; Female; Heterografts; Humans; Indazoles; Mutation; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2018 |
Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States.
Topics: Cost-Benefit Analysis; Decision Support Techniques; Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Quality-Adjusted Life Years; Survival Rate; United States | 2019 |
Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer.
Topics: Clinical Decision-Making; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Indazoles; Models, Economic; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; United States | 2018 |
Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
Topics: Antineoplastic Agents; Budgets; Female; Health Expenditures; Humans; Indazoles; Models, Econometric; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Survival Analysis; United States | 2019 |
Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models.
Topics: Animals; Antibodies; Base Sequence; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Female; Gene Expression Profiling; Humans; Immunotherapy; Indazoles; Interferons; Mice; Mice, Inbred C57BL; Mutation; Neoplasm Transplantation; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Programmed Cell Death 1 Receptor | 2019 |
Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Indazoles; Indoles; Maintenance Chemotherapy; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Precision Medicine; Randomized Controlled Trials as Topic | 2019 |
Fighting against the challenge of treating patients with late-line ovarian cancer: are we there yet?
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines | 2019 |
Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States".
Topics: Cost-Benefit Analysis; Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; United States | 2019 |
Response to 'Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States"'.
Topics: Cost-Benefit Analysis; Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; United States | 2019 |
Long-term cardiovascular effects of vandetanib and pazopanib in normotensive rats.
Topics: Animals; Arterial Pressure; Disease Models, Animal; Drug Administration Schedule; Humans; Hypertension; Indazoles; Male; Piperidines; Pyrimidines; Quinazolines; Random Allocation; Rats; Rats, Sprague-Dawley; Sulfonamides | 2019 |
Comment on: "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States".
Topics: Cost-Benefit Analysis; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; United States | 2019 |
Targeting PARP and autophagy evoked synergistic lethality in hepatocellular carcinoma.
Topics: Animals; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Proliferation; Chloroquine; Drug Synergism; Gene Expression Regulation, Neoplastic; Heterografts; Histones; Humans; Indazoles; Liver Neoplasms; Mice; Oncogene Protein v-akt; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; TOR Serine-Threonine Kinases | 2020 |
Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
Topics: Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Indazoles; Indoles; Mice; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Wnt Signaling Pathway | 2019 |
Inhibition of EZH2 and immune signaling exerts synergistic antitumor effects in chronic lymphocytic leukemia.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocytes; Bridged Bicyclo Compounds, Heterocyclic; Down-Regulation; Drug Synergism; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Histones; Humans; Indazoles; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyridones; Pyrimidines; Quinazolinones; Signal Transduction; Sulfonamides; Tumor Microenvironment | 2019 |
Niraparib as maintenance therapy in a patient with ovarian cancer and brain metastases.
Topics: Aged; Brain Neoplasms; Cystadenocarcinoma, Serous; Disease-Free Survival; Female; Humans; Indazoles; Maintenance Chemotherapy; Neoplasm Grading; Ovarian Neoplasms; Piperidines; Treatment Outcome | 2019 |
Chemotherapy-free, but not quite free chemotherapy.
Topics: Bevacizumab; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Platinum | 2019 |
Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial.
Topics: BRCA1 Protein; BRCA2 Protein; Disease Progression; Drug Administration Schedule; Female; Germ-Line Mutation; Humans; Indazoles; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Time Factors | 2019 |
Highly enantioselective rhodium-catalyzed cross-coupling of boronic acids and racemic allyl halides.
Topics: Allyl Compounds; Boronic Acids; Catalysis; Chemistry Techniques, Synthetic; Indazoles; Piperidines; Rhodium; Stereoisomerism | 2019 |
An Agonist of the CXCR4 Receptor Strongly Promotes Regeneration of Degenerated Motor Axon Terminals.
Topics: Animals; Benzylamines; Cyclams; Heterocyclic Compounds; Indazoles; Mice; Mice, Inbred Strains; Motor Neurons; Nerve Degeneration; Nerve Regeneration; Neuromuscular Junction; Piperidines; Presynaptic Terminals; Primary Cell Culture; Pyridines; Rats; Receptors, CXCR4; Spider Venoms | 2019 |
Niraparib improves progression-free survival in ovarian cancer.
Topics: Clinical Trials, Phase III as Topic; Drug Administration Schedule; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Randomized Controlled Trials as Topic | 2019 |
Autophagy suppression enhances DNA damage and cell death upon treatment with PARP inhibitor Niraparib in laryngeal squamous cell carcinoma.
Topics: Autophagic Cell Death; Cell Cycle; Cell Line, Tumor; DNA Damage; Humans; Indazoles; Laryngeal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2019 |
Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Chloroquine; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Indazoles; Mice, Nude; Mice, SCID; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Xenograft Model Antitumor Assays | 2020 |
A CXCR4 receptor agonist strongly stimulates axonal regeneration after damage.
Topics: Animals; Axons; Benzylamines; Chemokine CXCL12; Cyclams; Disease Models, Animal; Heterocyclic Compounds; Indazoles; Mice; Mice, Inbred C57BL; Nerve Regeneration; Piperidines; Pyridines; Receptors, CXCR4; Schwann Cells; Sciatic Nerve; Sciatic Neuropathy | 2019 |
Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities.
Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Design; HIV; HIV Reverse Transcriptase; Humans; Indazoles; Microbial Sensitivity Tests; Molecular Structure; Piperidines; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2020 |
Chemotherapy-free strategy for platinum-sensitive recurrent ovarian cancer.
Topics: Bevacizumab; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Platinum | 2019 |
Personalized Medicine for Primary Treatment of Serous Ovarian Cancer.
Topics: Cystadenocarcinoma, Serous; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Precision Medicine | 2019 |
BRCA Mutations and Homologous Recombination Repair Deficiency in Treatment With Niraparib Combined With Pembrolizumab-Reply.
Topics: Antibodies, Monoclonal, Humanized; Female; Humans; Indazoles; Mutation; Ovarian Neoplasms; Piperidines; Recombinational DNA Repair | 2020 |
BRCA Mutations and Homologous Recombination Repair Deficiency in Treatment With Niraparib Combined With Pembrolizumab.
Topics: Antibodies, Monoclonal, Humanized; Humans; Indazoles; Mutation; Piperidines; Recombinational DNA Repair; Triple Negative Breast Neoplasms | 2020 |
[PARP inhibitors in first-line of ovarian cancers].
Topics: Benzimidazoles; Clinical Trials as Topic; Female; Genes, BRCA1; Genes, BRCA2; Humans; Indazoles; Maintenance Chemotherapy; Ovarian Neoplasms; Phenotype; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2020 |
The kinase polypharmacology landscape of clinical PARP inhibitors.
Topics: Antineoplastic Agents; Binding Sites; Cyclin-Dependent Kinases; Dyrk Kinases; HEK293 Cells; Humans; Indazoles; Indoles; Isoenzymes; Molecular Docking Simulation; Neoplasms; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polypharmacology; Protein Binding; Protein Interaction Domains and Motifs; Protein Serine-Threonine Kinases; Protein Structure, Secondary; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Substrate Specificity | 2020 |
Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints.
Topics: Cell Cycle Checkpoints; Cell Line, Tumor; DNA Damage; Head and Neck Neoplasms; Humans; Indazoles; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Pyrazoles; Pyrimidinones; Radiation Tolerance | 2021 |
Design, Synthesis, and In Vitro Evaluation of Hydroxybenzimidazole-Donepezil Analogues as Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Chelating Agents; Cholinesterase Inhibitors; Donepezil; Humans; Indazoles; Ligands; Molecular Docking Simulation; Molecular Structure; Piperazine; Piperidines; Structure-Activity Relationship | 2020 |
Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Cost-Benefit Analysis; Drug Costs; Female; Humans; Indazoles; Indoles; Infusions, Intravenous; Markov Chains; Models, Statistical; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life; United States | 2020 |
PARP Inhibitors in Ovarian Cancer.
Topics: Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2020 |
Rapid and temporary improvement of depression and anxiety observed following niraparib administration: a case report.
Topics: Anxiety; Depression; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2020 |
Proton and photon radiosensitization effects of niraparib, a PARP-1/-2 inhibitor, on human head and neck cancer cells.
Topics: Cell Line, Tumor; Head and Neck Neoplasms; Humans; Indazoles; Photons; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Protons; Radiation-Sensitizing Agents | 2020 |
Involvement of POLA2 in Double Strand Break Repair and Genotoxic Stress.
Topics: Brain Neoplasms; Cell Line, Tumor; DNA Breaks, Double-Stranded; DNA Damage; DNA Polymerase I; DNA Repair; Etoposide; Gene Expression Regulation, Neoplastic; Glioma; Humans; Indazoles; Piperidines; Radiation, Ionizing; Survival Analysis; Up-Regulation | 2020 |
Nephrotoxicity Associated With Niraparib.
Topics: Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Kidney Diseases; Middle Aged; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Risk Factors | 2020 |
Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis.
Topics: Carcinoma, Ovarian Epithelial; Cost-Benefit Analysis; Decision Support Techniques; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Quality-Adjusted Life Years | 2020 |
PARP inhibitors combined with ionizing radiation induce different effects in melanoma cells and healthy fibroblasts.
Topics: Apoptosis; Cell Survival; Chemoradiotherapy; Drug Interactions; Fibroblasts; G2 Phase Cell Cycle Checkpoints; Homologous Recombination; Humans; Indazoles; Melanoma; Phthalazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Primary Cell Culture; Skin; Skin Neoplasms; Tumor Cells, Cultured | 2020 |
Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Community Health Centers; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Costs; Female; Follow-Up Studies; Gynecology; Humans; Indazoles; Indoles; Medical Oncology; Medication Therapy Management; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Randomized Controlled Trials as Topic; Retrospective Studies; Workload | 2020 |
Niraparib in the treatment of previously treated advanced ovarian, fallopian tube or primary peritoneal cancer.
Topics: Fallopian Tube Neoplasms; Female; Humans; Indazoles; Molecular Targeted Therapy; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Treatment Outcome | 2020 |
Clinical PARP inhibitors do not abrogate PARP1 exchange at DNA damage sites in vivo.
Topics: Binding Sites; Catalytic Domain; Cell Line, Tumor; DNA Damage; DNA Repair; Fluorescence Resonance Energy Transfer; Green Fluorescent Proteins; Humans; Indazoles; Kinetics; Molecular Imaging; NAD; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Recombinant Proteins; X-ray Repair Cross Complementing Protein 1 | 2020 |
An agonist of the CXCR4 receptor accelerates the recovery from the peripheral neuroparalysis induced by Taipan snake envenomation.
Topics: Action Potentials; Animals; Elapid Venoms; Indazoles; Mice; Mice, Inbred C57BL; Motor Neurons; Neuromuscular Junction; Paralysis; Piperidines; Pyridines; Receptors, CXCR4 | 2020 |
Assessment of acute kidney injury related to small-molecule protein kinase inhibitors using the FDA adverse event reporting system.
Topics: Acute Kidney Injury; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Azetidines; Benzamides; Female; Hospital Mortality; Hospitalization; Humans; Indazoles; Male; Middle Aged; Odds Ratio; Pharmacovigilance; Piperidines; Protein Kinase Inhibitors; Retrospective Studies; Risk Assessment; Sirolimus; United States; United States Food and Drug Administration; Young Adult | 2020 |
Avatrombopag Optimizes Response to Niraparib by Managing Thrombocytopenia Associated with Poly-ADP Ribose Polymerase (PARP) Inhibition in Ovarian Cancer and Breast Cancer: A Case Series.
Topics: Adenosine Diphosphate Ribose; Breast Neoplasms; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Thiazoles; Thiophenes; Thrombocytopenia | 2020 |
Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States.
Topics: Antineoplastic Agents, Immunological; Bevacizumab; Carcinoma, Ovarian Epithelial; Computing Methodologies; Cost-Benefit Analysis; Female; Genes, BRCA1; Genes, BRCA2; Homologous Recombination; Humans; Indazoles; Maintenance Chemotherapy; Medicare; Neoplasm Staging; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; United States | 2020 |
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colorectal Neoplasms; Female; Humans; Indazoles; Irinotecan; Mice; Mice, Nude; Mutation; Piperidines | 2021 |
Histone Parylation factor 1 contributes to the inhibition of PARP1 by cancer drugs.
Topics: Antineoplastic Agents; Benzamides; Benzimidazoles; Binding Sites; Carrier Proteins; Catalysis; Catalytic Domain; DNA Repair Enzymes; Humans; Indazoles; Indoles; Nuclear Proteins; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Protein Binding | 2021 |
Successful treatment of a patient with brain metastases from endometrial cancer using Niraparib: a case report.
Topics: Brain Neoplasms; China; Endometrial Neoplasms; Female; Humans; Indazoles; Middle Aged; Piperidines | 2021 |
How to start niraparib in real-world Asian ovarian cancer patients?
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines | 2021 |
Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL.
Topics: Adenine; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Glycine; HSP90 Heat-Shock Proteins; Humans; Indazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Piperidines; Protein Kinase Inhibitors | 2021 |
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.
Topics: Aminopyridines; Aniline Compounds; Animals; Apoptosis; Benzamides; Carbazoles; Cell Line; Cell Survival; Crizotinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Immunoblotting; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mice, Inbred BALB C; Molecular Dynamics Simulation; Neoplasm Recurrence, Local; Piperidines; Proto-Oncogene Proteins; Pyrazines; Pyrazoles; Receptor Protein-Tyrosine Kinases | 2021 |
[New drug approval: Olaparib and niraparib - first line in ovarian cancer].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Female; Humans; Indazoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2021 |
Niraparib in the maintenance treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: safety and efficacy.
Topics: Carcinoma, Ovarian Epithelial; Fallopian Tubes; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines | 2021 |
SWATH-MS proteomics of PANC-1 and MIA PaCa-2 pancreatic cancer cells allows identification of drug targets alternative to MEK and PI3K inhibition.
Topics: Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Humans; Indazoles; Mass Spectrometry; Mitogen-Activated Protein Kinase Kinases; Oxadiazoles; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proteome; Proteomics; Signal Transduction; Sulfonamides | 2021 |
PARP inhibitor niraparib as a radiosensitizer promotes antitumor immunity of radiotherapy in EGFR-mutated non-small cell lung cancer.
Topics: Animals; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Chemokine CCL5; Chemokine CXCL10; Chemoradiotherapy; DNA Breaks, Double-Stranded; Female; Fluorescent Antibody Technique; Genes, erbB-1; Humans; Immune System; Immunocompetence; Indazoles; Interferon Regulatory Factor-3; Interferon-beta; Lung Neoplasms; Lymphocytes, Tumor-Infiltrating; Membrane Proteins; Mice; Mice, Inbred C57BL; Mutation; Nuclear Proteins; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Serine-Threonine Kinases; Radiation Tolerance; Radiation-Sensitizing Agents; Real-Time Polymerase Chain Reaction; TATA Box Binding Protein-Like Proteins; Tumor Stem Cell Assay | 2021 |
NPRL2 reduces the niraparib sensitivity of castration-resistant prostate cancer via interacting with UBE2M and enhancing neddylation.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Atlases as Topic; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Cell Movement; Cell Proliferation; Databases, Genetic; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NEDD8 Protein; Piperidines; Prostatic Neoplasms, Castration-Resistant; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Signal Transduction; Survival Analysis; Tumor Suppressor Proteins; Ubiquitin-Conjugating Enzymes; Xenograft Model Antitumor Assays | 2021 |
Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Female; Humans; Indazoles; Mitochondria; Nuclear Proteins; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Signal Transduction; Synthetic Lethal Mutations; Twist-Related Protein 1 | 2021 |
The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China.
Topics: Adult; Aged; China; Female; Humans; Indazoles; Middle Aged; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2021 |
PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation.
Topics: Cell Cycle; Cell Line, Tumor; Fibroblasts; Humans; Indazoles; Melanoma; Phthalazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Radiation Tolerance | 2021 |
Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer.
Topics: Cost-Benefit Analysis; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines | 2022 |
Niraparib for Advanced Breast Cancer with Germline
Topics: BCG Vaccine; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Female; Germ Cells; Germ-Line Mutation; Humans; Indazoles; Nitriles; Piperidines | 2021 |
Investigation of the Complexes Formed between PARP1 Inhibitors and PARP1 G-Quadruplex at the Gene Promoter Region.
Topics: Benzimidazoles; DNA; G-Quadruplexes; Humans; Indazoles; Magnetic Resonance Spectroscopy; Models, Molecular; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Promoter Regions, Genetic | 2021 |
Real-world Experience of Niraparib in Newly-diagnosed Epithelial Ovarian Cancer.
Topics: Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Drug Tapering; Feasibility Studies; Female; Humans; Indazoles; Maintenance Chemotherapy; Neoplasm Staging; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Republic of Korea; Retrospective Studies; Survival Analysis; Treatment Outcome | 2021 |
Adherence to PARP inhibitor therapy among women with ovarian cancer.
Topics: Female; Humans; Indazoles; Medication Adherence; Middle Aged; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Retrospective Studies | 2021 |
Budget impact analysis of niraparib for first-line maintenance therapy in advanced ovarian cancer from a US payer perspective.
Topics: Adult; Aged; Budgets; Cost-Benefit Analysis; Female; Humans; Indazoles; Middle Aged; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; United States | 2021 |
Suppression of isoprenylcysteine carboxylmethyltransferase compromises DNA damage repair.
Topics: Animals; Apoptosis; Benzamides; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; DNA Damage; DNA Repair; Female; Genetic Vectors; HEK293 Cells; Humans; Indazoles; MAP Kinase Signaling System; Mice; Mice, SCID; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Protein Methyltransferases; Ribonucleosides; RNA, Small Interfering; Tumor Burden; Xenograft Model Antitumor Assays | 2021 |
Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer.
Topics: B7-H1 Antigen; Female; Humans; Immunity; Indazoles; Ovarian Neoplasms; Piperidines | 2021 |
Chronic stress induces platinum and Niraparib resistance in mouse models of ovarian cancer.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Indazoles; Mice, Inbred BALB C; Mice, Inbred C57BL; Middle Aged; Models, Biological; Ovarian Neoplasms; Piperidines; Platinum; Stress, Psychological | 2022 |
Proteomic Analysis Reveals Low-Dose PARP Inhibitor-Induced Differential Protein Expression in BRCA1-Mutated High-Grade Serous Ovarian Cancer Cells.
Topics: Cell Line, Tumor; Chromatography, High Pressure Liquid; Female; Humans; Indazoles; Indoles; Mass Spectrometry; Mitochondria; Neoplasm Grading; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Proteomics; Signal Transduction | 2022 |
Switching PARP inhibitors as an effective approach for niraparib-induced erythema multiforme.
Topics: Erythema Multiforme; Humans; Indazoles; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2022 |
Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Indazoles; Lung Neoplasms; Mice; Mice, Nude; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Radiation Tolerance; Radiation-Sensitizing Agents | 2022 |
Niraparib Shows Superior Tissue Distribution and Efficacy in a Prostate Cancer Bone Metastasis Model Compared with Other PARP Inhibitors.
Topics: Animals; Bone Neoplasms; Humans; Indazoles; Male; Mice; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prostate; Prostatic Neoplasms; Tissue Distribution | 2022 |
Indirect comparison of three PARP inhibitors (olaparib, niraparib, and rucaparib) as maintenance treatment in ovarian carcinoma patients responding to platinum therapy.
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors | 2022 |
Addendum: A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study.
Topics: Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines | 2022 |
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer.
Topics: Breast Neoplasms; Female; Humans; Indazoles; Neoadjuvant Therapy; Pilot Projects; Piperidines | 2022 |
Real-world outcomes of niraparib treatment in patients with ovarian cancer: a multicenter non-interventional study in China.
Topics: China; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines | 2023 |
Re: Niraparib and Abiraterone Acetate for Metastatic Castration-resistant Prostate Cancer.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Humans; Indazoles; Male; Piperidines; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2023 |
Niraparib/abiraterone acetate (Akeega) for prostate cancer.
Topics: Abiraterone Acetate; Humans; Indazoles; Male; Piperidines; Prostatic Neoplasms | 2023 |
Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China.
Topics: Aged; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines | 2023 |